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ABSTRACT: We report the discovery of compound 4a, a potent β-lactam-based monoacylglycerol lipase (MGL) inhibitor
characterized by an irreversible and stereoselective mechanism of action, high membrane permeability, high brain penetration
evaluated using a human in vitro blood−brain barrier model, high selectivity in binding and affinity-based proteomic profiling assays,
and low in vitro toxicity. Mode-of-action studies demonstrate that 4a, by blocking MGL, increases 2-arachidonoylglycerol and behaves
as a cannabinoid (CB1/CB2) receptor indirect agonist. Administration of 4a in mice suffering from experimental autoimmune
encephalitis ameliorates the severity of the clinical symptoms in a CB1/CB2-dependent manner. Moreover, 4a produced analgesic
effects in a rodent model of acute inflammatory pain, which was antagonized by CB1 and CB2 receptor antagonists/inverse agonists.
4a also relieves the neuropathic hypersensitivity induced by oxaliplatin. Given these evidence, 4a, as MGL selective inhibitor, could
represent a valuable lead for the future development of therapeutic options for multiple sclerosis and chronic pain.
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■ INTRODUCTION
Multiple sclerosis (MS) is a neuroinflammatory autoimmune
disease characterized by demyelination and axonal damage lead-
ing to loss of cerebral functions.1 The treatment landscape of MS
includes several anti-inflammatory agents and monoclonal anti-
bodies for immunotherapy. Besides demyelination and inflam-
mation, thought to play the major role inMS progression, central
neuronal defects also occur and have been associated with the
onset of symptoms such as spasticity and pain.
In the past few years, an increasing body of evidence has
suggested that cannabinoids may have beneficial effects on the
symptoms of MS.2 More recently, attention has focused on small
molecules modulating the endocannabinoid system, although
more investigation is needed to prove whether endocannabinoid
system modulation may represent a valuable therapeutic option
to successfully reverse the clinical progression of MS.3 In fact,
therapeutic inhibition of endocannabinoid degrading enzymes
increases the endocannabinoids (ECs) tissue levels and is less
likely to cause psychoactive effects than direct agonism of
cannabinoid receptor 1 (CB1) while maintaining other beneficial
effects of CB1/2 receptors activation.4−6
ECs such as Anandamide (AEA) and 2-arachidonoyl-sn-glycerol
(2-AG) are signaling lipids that exert their biological actions by
interacting with cannabinoid receptors (CBRs);7 they modulate
multiple physiological processes including pain, inflammation,
appetite, memory, and emotion.8 In the brain, 2-AG is produced
by diacylglycerol lipases and it is deactivated through mono-
acylglycerol lipase (MGL)-mediated hydrolysis. Because of its
prominent role in 2-AG catabolism, selective inactivation of
MGL represents an attractive approach for eliciting the desirable
effects of indirect CBR activation. MGL is a serine hydrolase with
a catalytic triad represented by Ser122, His269, and Asp239.9
Inhibitors of 2-AG degradation have been developed such
as the carbamate biphenyl-3-ylcarbamic acid cyclohexyl ester
(URB602),10−12 the tetrahydrolipstatin (S)-1-((2S,3S)-3-
hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamidoacetate
(OMDM169),13 the 4-(bis-benzo[1,3]dioxol-5-ylhydroxy-meth-
yl)piperidine-1-carboxylic acid 4-nitro-phenyl ester 1
(JZL184),14 the ureidic 4-(bis(4-fluorophenyl)methyl)-
piperazin-1-yl)(1H-1,2,4-triazol-1-yl)methanone 2 (SAR629),15
and their analogue (4-(bis(benzo[d][1,3]dioxol-5-yl)methyl)-
piperidin-1-yl)(1H-1,2,4-triazol-1-yl)methanone 3 (JJKK-048).16
Despite the variety of MGL inhibitors available, the structural
diversity of chemical templates explored to date remains poor.
Compound 1, which shares with most MGL inhibitors the
diphenylmethane core, is frequently used as experimental tool
but it exhibits only submicromolar activity against the human
MGL (hMGL) enzyme.
We describe herein the development of a set of β-lactam-based
inhibitors (4a−h, Chart 1) of human MGL which led to the
identification of 4a as the prototypic compound of this
class of analogues. 4a was characterized as a novel, ultra-
potent hMGL inhibitor, with high selectivity toward the AEA-
inactivating enzyme, fatty acid amide hydrolase (FAAH), other
serine hydrolases from the rat brain proteome, and CBRs. The
unique profile of this prototypic inhibitor combines selectivity,
potency, and favorable pharmacokinetic properties, highlighting
its potential as a novel MGL inhibitor for further development
(Table 1). As expected for a potent and selective MGL inhibitor,
in vivo administration of 4a reduced the clinical severity of the
disease inmice suffering from experimental autoimmune enceph-
alomyelitis (EAE), a rodent demyelinating disease model.17
In vivo tests confirmed the analgesic profile of 4a in mouse
models and evidenced a clear-cut dependence of its pharmaco-
logical efficacy upon the increased 2-AG levels and subsequent
indirect CBRs modulation. Remarkably, the efficacy of 4a further
supports the hypothesis2 of a tight intersection between the
endocannabinoid system and MS.
■ CHEMISTRY
Synthesis of compounds (±)-, (+)-, and (−)-4a, (±)-4b−h,
(±)-5a−e, (±)-6a−e, (±)-7, (±)-8, and 9 is reported in
Schemes 1−3.
Aldehydes 10a−c were reacted with 4-amino-1-benzylpiper-
idine to form the intermediate imines 11a−c. These latter were
subjected to the Staudinger reaction18 using the suitable phenyl-
acetic acid, in the presence of triphosgene, to obtain the β-lactam
systems (±)-5a−e in the trans configuration. The benzyl groups
of (±)-5a−e were then cleaved by means of a palladium cata-
lyzed hydrogenation leading to free amines (±)-6a−e. Amines
(±)-6a−e were reacted with 1H-1,2,4-triazole in the presence of
phosgene and DMAP, providing final compound (±)-4a,e−h.
Enantiomerically pure amines (3R,4S)-(+)-6a and (3S,4R)-
(−)-6a, separated by HPLC as reported in the Supporting
Information, were also submitted to final reaction with 1H-1,2,4-
triazole in the presence of phosgene, leading to enantiomerically
pure final compounds (3R,4S)-(+)-4a and (3S,4R)-(−)-4a,
respectively. Compounds 4b, 4c, and 4d were prepared by
reaction of amine (±)-6a with 4-nitrophenyl chloroformate, 1,1-
carbonyldiimidazole, 1,1,1,3,3,3-hexafluoroisopropanol, and tri-
phosgene, respectively (Scheme 1).
Compound (±)-12 was prepared by alane reduction of
compound (±)-5a. Subsequent hydrogenation and treatment of
the resulting amine (±)-13with 1H-1,2,4-triazole, phosgene, and
DMAP led to derivative (±)-7 (Scheme 2).
Catalyst 16 (Scheme 3), used for the diastereoselective synthesis
of the trans-3,4-diarylsubstituted β-lactam system, was prepared by
refluxing 14 with 3-amino-1-propanol in chlorobenzene and
successive treatment of the intermediate 15 with mesyl chlo-
ride in the presence of N,N-diisopropylethylamine (DIPEA).19
Meanwhile, imine 17, obtained by heating at reflux 10a with
4-toluenesulfonamide in absolute ethanol, was subjected to the
cyclization reaction20 using 4-fluorophenylacetic acid, in the
presence of tosyl chloride and catalyst 16, obtaining the
Chart 1. Representative Diphenylmethane Inhibitors
(Compounds 1−3) and General Structure of Title
Compounds 4a−h
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N-tosylated trans-β-lactam (±)-18. This latter was treated
with a solution of SmI2 in tetrahydrofuran to give the final
compound (±)-8. Compound 9 was prepared by reaction of
piperidine (19) with 1H-1,2,4-triazole and phosgene in the
presence of DMAP.
To evaluate the stereoselectivity of the interaction of (±)-4a
with hMGL (see Table 1 in next paragraph), we resolved the
racemic mixture of amine (±)-6a by using chiral HPLC (see
Supporting Information). The two amines, (+)-6a and (−)-6a,
showing an optical purity >98% (Supporting Information,
Figure S2), underwent the final reaction to yield the two enan-
tiomers of 4a. Enantiomers (+)-6a and (−)-6a yielded (+)-4a and
(−)-4a, respectively. The absolute configuration of (+)-trans-6a
was established by means of electronic circular dichroism (ECD)
spectroscopy combined with time-dependent density functional
theory (TD-DFT) calculations of the theoretical chiroptical
properties of (3R,4S)-6a.21 As shown in Figure 1, the theoretical
UV and ECD spectra of (3R,4S)-6a are in agreement with the
experimental spectra of (+)-trans-6, allowing us to assign a (3R,4S)
configuration to (+)-6a and, consequently, to (+)-4a.
■ RESULTS AND DISCUSSION
Rational Design, Structure−Activity Relationships, and
Molecular Modeling Studies. The MGL-2 cocrystal
structure22 defined the structural basis for MGL inhibition.
This complex also shed light on the size of the lipophilic portion
of the MGL binding pocket, which is of particular interest for
designing novel and selective enzyme ligands. An in-depth
examination of this X-ray structure, combined with the analysis of
the structural elements of other diphenylmethane inhibitors,
allowed us to develop a novel 3D pharmacophore model and to
rationally design innovative MGL inhibitors based on a β-lactam
skeleton (Chart 1, and Figure S1 of the Supporting Information).
In particular, to improve the binding properties over current
inhibitors such as 1, we chose the trans-3,4-diarylsubstituted
β-lactam structural motif to obtain the correct distance and
reciprocal orientation of the aromatic rings (see Supporting
Information for details). In this frame, the combination of the
4-fluorophenyl and the methylene-3,4-dioxyphenyl moieties
provides the key hydrophobic interactions with the enzyme
(Supporting Information, Figure S1) and guarantees an improved
Scheme 1. Synthesis of Title Compounds 4a−ha
aReagents and conditions: (a) 4-amino-1-benzylpiperidine, EtOH, 80 °C, 12 h; (b) triphosgene, dry DCM, 50 °C, 0.5 h, TEA, 50 °C, 12 h;
(c) H2, Pd/C 10%, MeOH, 25 °C, 2 h; (d) 1H-1,2,4-triazole, phosgene (20% in toluene), DMAP, dry DCM, 25 °C, 12 h; (e) for 4b, 4-nitro-
phenyl chloroformate, TEA, dry DCM, 25 °C, 12 h; for 4c, 1,1-carbonyldiimidazole, dry DCM, 25 °C, 12 h; for 4d, 1,1,1,3,3,3-
hexafluoroisopropanol, triphosgene, DIPEA, dry DCM, 25 °C, 12 h; for 4a,e−h, 1H-1,2,4-triazole, phosgene (20% in toluene), DMAP, dry DCM,
25 °C, 12 h.
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drug-like profile. The diaryl β-lactam system of compounds 4a−h
represents a novelty in the field of MGL inhibition because the
potent inhibitors so far described (compounds 1−3) all share a
diphenylmethane-based structure.
The experimental data shown in Table 1 confirmed that the
β-lactam is a key substructure for potent and selective MGL
inhibition. When compound 4a was tested in vitro for its ability
to inhibit human and ratMGL, it resulted in being a very potent
inhibitor of hMGL (IC50 = 7.4 nM, Table 1) and a picomolar
inhibitor of ratMGL (rMGL, IC50 = 250 pM). Selectivity toward
human recombinant FAAH was measured, and 4a proved to
be more than 380-fold selective over human FAAH (hFAAH)
(Table 1). Notably, the two enantiomers showed a stereo-
selective interaction with hMGL (Table 1), the eutomer (3R,4S)-
(+)-4a being nearly 7 times more potent than the distomer
(3S,4R)-(−)-4a. The selectivity versus hFAAH was maintained,
with both enantiomers still being highly selective for hMGL
(Table 1).
Further in vitro tests revealed that 4a does not significantly
interact (IC50 > 10 μM) with either CB1 or CB2 receptors in
displacement assays carried out with a high affinity radiolabeled
ligand of such receptors. A time-course experiment showed that
4a inhibits hMGL with an IC50 = 195.8 nM (Table 2) when the
assay was conducted without the standard 10 min preincubation,
thus suggesting an irreversible mechanism of action.
We developed and tested a small set of analogues of 4a (4b−h,
Table 1) in order to investigate: (i) the role played by the leaving
group linked to the piperidine ring (4b−d, Table 1) and (ii) the
effect of a small number of focused substitutions aimed at modi-
fying steric hindrance and electronic properties of the aromatic
systems placed on the β-lactam skeleton (4e−h, Table 1).
When studying the mechanism of action of irreversible MGL
inhibitors, we applied the concept advanced by Aaltonen and co-
workers16 according to whom the effects of the leaving group are
strictly dependent upon its physicochemical properties, although
steric hindrance may also play a role. In fact, we found that the
effect on potency seems to be related to the pKa of the leaving
group’s conjugated acid (ideal pKa ∼ 10). Accordingly, the best
profile among compounds 4a−d was achieved with the triazole
(pKa = 10), while the imidazole (pKa = 14) provided a 1500-fold
Scheme 3. Synthesis of β-Lactam (±)-8, and of Compound 9a
aReagents and conditions: (a) 3-amino-1-propanol, DIPEA, chlo-
robenzene, 130 °C, 4 h; (b) TEA, MsCl, dry DCM, 0−25 °C, 1.5 h
then MeOH, TEA, 50 °C, 1.5 h; (c) 4-toluensulfonamide, BF3·Et2O,
dry toluene, 130 °C, 12 h; (d) 4-fluorophenylacetic acid, TsCl, DIPEA,
dry DCM, 0 °C, 30 min then 16, DIPEA, 25 °C, 5 h; (e) SmI2 0.1 N
solution in THF, dry THF, 25 °C, 15 min; (f) 1H-1,2,4-triazole,
phosgene (20% in toluene), DMAP, dry DCM, 25 °C, 12 h.
Figure 1. Absolute configuration determination of compound 6a.
Experimental UV and ECD spectra of (+)-trans-6a (solid line)
compared to the PBE0/TZ2P//B97D/TZ2P calculated spectra of
(3R,4S)-6a (dashed line). Computational details are given in
Experimental Section and Supporting Information.
Scheme 2. Synthesis of Analogue (±)-7a
aReagents and conditions: (a) LiAlH4, AlCl3, dry THF, 0 °C, 45 min
then 10% aqueous NaOH, 0 °C, 30 min; (b) H2, 10% Pd/C, MeOH,
25 °C, 2 h; (c) 1H-1,2,4-triazole, phosgene (20% in toluene), DMAP,
dry DCM, 25 °C, 12 h.
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Table 1. Inhibition Activity of Compounds 4a−h, 5a, 6a, and 7−9 onHuman and RatMGL Enzymes (IC50, nM) and onHuman or
Rat FAAH Enzymes (IC50, nM)
a
aTests were performed as described in the Experimental Section; values are means of three experiments and all SD are within 10%. bhFAAH IC50.
cCOS cells MGL IC50.
drFAAH IC50.
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reduction in potency (4b vs 4a, Table 1), the p-nitrophenoxy
group (1) (pKa = 7) displayed a 200-fold drop of potency (4c vs 4a),
and the hexafluoroisopropyl alcohol (pKa = 9) gave an analogue
(4d) 17 times less potent than 4a.
The modification of steric hindrance and electronic properties
of the aromatic systems placed on the β-lactam skeleton was also
crucial for potency and selectivity of our MGL inhibitors. The
replacement of the 4-fluoro of 4a with a methoxy group led to
inhibitor 4e with a slight loss of inhibitory potency (IC50 =
13.2 nM, Table 1). Compound 4f, in which the methylene-3,4-
dioxyphenyl moiety was replaced by a dimethoxyphenyl system,
resulted in a 10 times less potent analogue (IC50 = 61.4 nM,
Table 1) and displayed the lowest degree of selectivity toward
FAAH (IC50 rFAAH/IC50 hMGL = 12). Substitution (with
methoxy groups) at para and meta positions on both the aroma-
tic rings (4g) was detrimental and led to a sensible decrease of
MGL inhibition potency (IC50 = 251.3 nM). By contrast, a
decreased steric hindrance, by substitution (with methoxy groups)
at the para positions only (4h), triggered a partial recovery of
inhibitory potency (IC50 = 23.3 nM).
Taken together, these studies point out to the 4-F-phenyl
system at C3 of the β-lactam skeleton and a methylene-3,4-
dioxyphenyl moiety at C4, combined to the triazole system, (4a)
as the optimal structural arrangement for both potency and
selectivity.
Further studies were dedicated to gain insight into the mecha-
nism of action of 4a. We applied a molecular deconstruction
procedure aimed at defining the essential structural determinants
contributing to the high potency of 4a (Chart 2). To this aim,
synthetic intermediates 5a and 6a were also tested in order to
assess the importance of the leaving triazole group. In line with
the hypothesized irreversible mechanism of action, both amines
5a and 6a lacked inhibitory activity toward MGL (Table 1). We
also explored the role of the azetidinone system by synthesizing
the azetidine 7. This compound, displaying a 2-fold drop in
inhibitory potency (IC50 = 376 nM), underlined the pivotal role
played by the β-lactam amide carbonyl (Table 1). Finally, the
isolated 3,4-trans-diaryl-β-lactam system (8) and the piperidine
triazole urea disconnection unit 9 were found to be extremely
weak MGL inhibitors (IC50 > 10 μM). Overall, molecular
deconstruction confirmed the original design hypothesis leading
to 4a as a synergistic combination of key structural elements for
the fine-tuning of potency.
The interaction of 4a with rMGL was also studied by
combining top-down and bottom-up proteomics experiments
(Figure 2) (see Supporting Information for details). These
studies, which were consistent with a covalent interaction of 4a
with MGL, also indicated that the covalent MGL−4a adduct was
achieved with 1:1 stoichiometry, under the assay conditions.
Furthermore, the outcome of the bottom-up proteomic analyses,
performed to map the binding site of 4a in MGL, indicated that
the carbamoyl adduct of the tryptic peptide with 4a (Figure 2C)
contains six serine residues, including the catalytic Ser122.
Tandemmass analysis allowed us to unequivocally assign Ser122
as the site of modification induced by the nucleophilic attack
on the urea moiety of 4a (Figures S2−S5; see Supporting
Information for details).
The stereoselective interaction of 4a with hMGL was
investigated by docking studies (Glide, version 5.7, Schrödinger,
LLC, New York, NY, 2011). The eutomer (3R,4S)-4a shows a
different pattern of interactions with respect to the distomer
Table 2. Inhibition Activity of Reference Compound 1 and
Compounds 4a, (3R,4S)-(+)-4a, and (3S,4R)-(−)-4a on
Human MGL (IC50, nM)
a
IC50 hMGL (nM)
1 4440 ± 268
4a 195.8 ± 9
(3R,4S)-(+)-4a 104.4 ± 12
(3S,4R)-(−)-4a 728.5 ± 21
aThe effect of the compounds on MGL activity was measured after a
20 min of incubation with the enzyme in the presence of the specific
substrate, as described in the Experimental Section; values are means
of three experiments and all SD are within 10%.
Chart 2. Molecular Deconstruction Units of Compound 4a
Figure 2. Investigation of the mechanism of action of compound 4a by
high resolution mass spectrometry experiments. Multiply charged mass
spectra of intact rMGL naiv̈e (A) or incubated with 4a (B) and
nucleophilic attack of Ser122 on the urea moiety of 4a, with formation of
a carbamate (C).
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(3S,4R)-4a (Figure 3A,B). (3R,4S)-4a establishes a series of
H-bonds with His269, Ala51, Met123, and with the catalytic
Ser122, while (3S,4R)-4a only interacts with Ser122 and Ala51.
These differences of interactions are translated into slightly
different Glide XP score values ((3R,4S)-4a −11.181 kcal/mol,
and (3S,4R)-4a −10.608 kcal/mol) and in different estimated
free-binding energy values calculated by using PrimeMM/GBSA
(ΔGbind(3R,4S)-4a = −119.05 kcal/mol, and ΔGbind(3S,4R)-4a
=−117.39 kcal/mol). Notably, the key interactions with His269,
Ala51, and Met123, the two latter residues being constituents
of the oxyanion hole, are relevant for MGL inhibition.9 Our
computational analysis also highlights the peculiar interactions of
both enantiomers into the hMGL binding site, with the catalytic
residues (Ser122 and His269 for (3R,4S)-4a and only Ser122 for
(3S,4R)-4a) and with the oxyanion hole residues (Ala51 and
Met123 for (3R,4S)-4a and only Ala51 for (3S,4R)-4a).
Proteomic analysis proved the formation of a carbamoylated
adduct of the enzyme with 4a. This data suggests the formation
of an initial tetrahedral intermediate which was also probed,
in silico, by a covalent docking approach. A tetrahedral com-
plex generated by using GOLD software23 for (3R,4S)-4a and
(3S,4R)-4a in complex with hMGL (Figure 3C) highlighted
that the binding mode found from classical docking studies
(Figure 3A−C) is maintained and (3R,4S)-4a and (3S,4R)-4a
similarly establish a H-bond with Gly50 (oxyanion hole residue),
deeply positioned into the binding site. Consequently, we can
assume that stereoselectivity of the interaction of 4a enantiomers
with hMGL can rely on the different enantiomer/enzyme recip-
rocal recognition at the early stage of interactions, as explained by
the docking studies (Figures 3A,B).
hFAAH/hMGL selectivity ratio (Table 1) for (3R,4S)- and
(3S,4R)-4a was explained by docking studies on the hFAAH
enzyme. (3R,4S)-4a and (3S,4R)-4a are not able to completely
reach the active site of the enzyme (Figures 4A,B), as they do not
lie in a favorable position into hFAAH active site but are accom-
modated in a pocket located in the upper part of the catalytic site.
The XP-scoring function explains the micromolar affinity for
hFAAH (4aGlide score values: −6.804 and −6.452 kcal/mol for
(3R,4S)- and (3S,4R)-4a respectively).
Affinity-Based Proteomic Profiling (ABPP) Assay.
Compound 4a was found to potently inhibit MGL with an
IC50 of∼10 nM in a competitive ABPP assay carried out in the rat
brain proteome and did not exhibit cross-reactivity with other rat
brain serine hydrolase off-targets up to 500 nM, including FAAH,
ABHD6, and ABHD12 (Figure 5A). Only at concentrations
≥500 nM some inhibition of lysophopholipase A1/2 was
observed (Figure 5B).
Preliminary in Vitro ADME+T Profiling. Besides its in vitro
profile, additional features that contribute to designate 4a as an
excellent MGL inhibitor are the lack of mutagenic effect in the
Salmonella typhimurium strains TA98 and TA100 at any of
the concentrations tested (following the assay conditions of the
Ames’ test, Figure 6) along with its experimentally determined
physicochemical features. 4a showed a favorable solubility
and a chemical stability profile at both neutral and acidic pH
(Supporting Information, Figure S7A). Metabolic stability to
hCYP3A4 and parallel artificial membrane permeability assay
confirmed the stability and high permeability through artificial
membranes of 4a (Supporting Information, Figures S7B,C).
Brain penetration, evaluated by using a human in vitro blood−
brain barrier model, is high (Papp = 47 × 10
−6 cm/s ± 6.81),
showing that 4amay easily cross the human blood−brain barrier.
Notably, the measured Papp for Lucifer yellow, the nonpermeant
molecule used as marker of endothelium integrity and coincu-
bated with 100 μM 4a (see Experimental Section for details), is
low (Papp = 9.48 × 10
−6 cm/s ± 1.68) and is in the same range
found when Lucifer yellow is administered alone. This data
indicates that transport of 4a across the blood−brain barrier is
not due to any toxic effect on the endothelium.
Cardiovascular adverse effects heavily contribute to drug
withdrawals from the market and represent one of the major
Figure 3.Molecular modeling studies on 4a. Docked pose of (3R,4S)-4a
(cyan sticks) (A) and of (3S,4R)-4a (green sticks) (B) in the hMGL
binding site (salmon cartoon). The catalytic triad is represented by
orange sticks, while oxyanion hole residues are represented by salmon
sticks. Nonpolar hydrogen atoms have been omitted. (C) Tetrahedral
complex of hMGL (salmon cartoon) and (3R,4S)-4a (cyan sticks) and
(3S,4R)-4a (green sticks). H-bonds are indicated by dotted lines in the
same colors of the ligands.
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hurdles in the development of new drugs. To evaluate the
potential cardiovascular toxicity of compound 4a, its effect on
cardiac mechanical function and electrocardiogram (ECG) in
Langendorff-isolated rat hearts was assessed, as previously
described.24 Under control conditions, left ventricle pressure
(LVP) and coronary perfusion pressure (CPP) values of 60.07 ±
8.96 and 57.45± 2.58 mmHg (n = 4), respectively, were obtained.
At the maximum concentration tested (1 μM), 4a significantly
increased CPP to 75.19 ± 7.80 mmHg (n = 4, ** P < 0.01,
repeated measures ANOVA and Dunnett’s post test). Moreover,
4a, up to 1 μM, did not affect surface ECG (Table 3).
At the maximum concentration tested, 4a increases coro-
nary perfusion pressure leaving unaltered heart contractility and
ECG, thus allowing us to exclude cardiac toxicity for this
compound.
In Vivo Efficacy of Compound 4a. Efficacy of 4a on the
Experimental Autoimmune Encephalomyelitis (EAE) Model of
MS in Rodents. Although no single animal model exists reca-
pitulating all the features of MS, EAE is considered an animal
model suitable for studying it25 because it shares some important
features with human MS, such as the chronic course and histo-
pathological evidence of demyelination and neuroinflamma-
tion.26 We therefore evaluated 4a in the myelin glycoprotein
35−55 (MOG35−55)-induced EAE rodent model (the disease was
induced as detailed in the Experimental Section). Drug pro-
phylactic treatment (4a, 3 mg/kg, ip) started at the asymptomatic
stage of disease at day 6 postimmunization (dpi), up to the acute
stage of the disease (21 ± 0.1 dpi, when the maximal score gravity
is observed). Administration of 4a clearly influenced the disease
progression, as assessed by the significant lower daily clinical score
observed in 4a-administered EAEmice when compared to vehicle-
treated EAE mice starting from 8 dpi, as well as by the dramatic
change in the cumulative score level (Figure 7). Interestingly, we
found that the reduction of the daily clinical score induced by
Figure 4. XP-Glide predicted binding mode into hFAAH (pink cartoon) binding site of (3R,4S)-4a (cyan sticks) (A) and of (3S,4R)-4a (green sticks)
(B). Catalytic triad (Ser241-Ser217-Lys142) is indicated by sticks, and the H-bonds are represented by black dotted line. Moreover, the crystallized
ligand was superposed to the docking complex, and it is represented by orange lines in order to highlight the impossibility of both enantiomers of 4a to
reach the catalytic Ser241 of hFAAH. In fact, (3R,4S)-4a (A) is able to interact with one of the residues belonging to the catalytic triad (Ser217), but no
interactions with the catalytic Ser241 are observed. For (3S,4R)-4a (B), no contacts with the catalytic triad are observed.
Figure 5. In vitro competitive ABPP of 4a using the serine hydrolase-
directed probe FP-Rh in the membrane fraction of the rat brain
proteome. (A) 4a potently and selectively inhibits FP-Rh labeling of
MGL, with lysophopholipase A1/2 (LYPLA1/2) being the only
detectable off-target (B) (from 500 nM to 1 μM of 4a).
Figure 6. Ames test performed on S. typhimurium TA98 and TA100
strains for compound 4a.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01812
J. Med. Chem. 2016, 59, 2612−2632
2619
prophylactic 4a could involve the modulation of the endocanna-
binoid system. Actually, administration (starting from 6 dpi for
14 days) of the selective CB1 antagonist/inverse agonist
N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide 20 (AM251)27 and the CB2
antagonist/inverse agonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)-
ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone 21
(AM630),28 each used at 1mg/kg, ip, both prevented the protecting
effect of 4a starting at 12 dpi. Although activation of both CB1 and
CB2 receptors by endogenous 2-AG could be beneficial for the
course of the disease,2 we found that the blockade of each one
of the two receptors significantly reduced the positive effects exerted
by 4a, leading us to conclude that in 4a-treated EAE mice both
receptors did not compensate but synergize with each other
mediating the 4a-induced amelioration of the clinical score. The
respective contribution of CB1 and CB2 in ameliorating the course
of the demyelinating disorder in EAEmice chronically administered
4a deserves further investigation to be clarified.
Changes in spontaneous locomotor activity were not observed
in 4a-administered control (nonimmunized) mice when compared
to control (not shown).
Following these encouraging results, we performed histo-
logical evaluation of myelin using the Luxol Fast Blue staining
(Figure 8). Pallor of Luxol Fast Blue stain is associated with a
reduction in the density of staining for myelin. Representative
images of spinal cord of each experimental group are shown in
Figure 8. In the spinal cord white matter of the control group, a
normal structural organization of myelin is evident. By contrast,
in EAE mice demyelinated areas are present (arrows). The EAE
mice treated with 4a exhibited myelin-density staining that was
Table 3. Effects of 4a on HR, RR, PQ, QRS, QT, QTc in Langendorff Perfused Rat Heartsa
4a (μM) HR (BPM) RR (ms) PQ (ms) QRS (ms) QT (ms) QTc (ms)
none 252.78 ± 9.28 238.38 ± 9.23 45.62 ± 4.49 14.26 ± 0.71 75.65 ± 0.87 155.26 ± 2.96
0.001 254.38 ± 9.83 236.93 ± 9.51 46.03 ± 4.81 14.02 ± 0.71 76.38 ± 1.14 157.13 ± 2.45
0.01 254.18 ± 8.35 236.80 ± 7.85 46.46 ± 5.25 13.50 ± 0.29 76.17 ± 0.48 156.30 ± 3.27
0.1 252.65 ± 7.66 238.15 ± 7.23 46.18 ± 5.84 13.75 ± 0.48 75.36 ± 1.85 154.60 ± 5.02
1 255.50 ± 7.36 235.48 ± 6.90 46.67 ± 5.23 13.75 ± 0.47 76.02 ± 1.84 156.78 ± 4.38
aEach value represents mean ± SEM (n = 4). HR, frequency; RR, cycle length; PQ, atrioventricular conduction time; QRS, intraventricular
conduction time; QT, duration of ventricular depolarization and repolarization, i.e., the action potential duration; QTc, corrected QT.
Figure 7. In vivo effects of compound 4a on EAE mice. Female C57BL/6J mice were immunized with the MOG35-55 peptide and were randomly
assigned to the following group: untreated EAEmice, 4a (3mg/kg ip) treated EAEmice; 4a (3mg/kg ip)/20 (1mg/kg)-treated EAEmice; 4a (3mg/kg
ip)/21 (1 mg/kg) treated EAE mice. Mice were administered drugs daily. 20 and 21 were administered 10 min before 4a. Clinical score is expressed as
average (media ± SEM) daily score (A−C) or as cumulative score (D). Data are means ± SEM from untreated EAE mice (A, white square, 7 animals),
from 4a (3 mg/kg ip) treated EAE mice (A−C white circle, 9 animals); from 4a (3 mg/kg ip)/20 (1 mg/kg) treated EAE mice (B, black triangle,
4 animals); from 4a (3 mg/kg ip)/21 (1 mg/kg) treated EAE mice (C, black square, 6 animals). *P < 0.05 vs EAE + vehicle 1 dpi; ∧P < 0.05 vs EAE +
vehicle in the same day; ∧∧P < 0.01 vs EAE + vehicle in the same day; ∧∧∧P < 0.001 vs EAE + vehicle.
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comparable to that of control animals. Treatment with 4a plus 20
or 21 revealed the presence of some demyelinated areas in
comparison to control animals and to 4a-treated groups, but
these areas were less extended than in EAE group (Figure 8).
In Figure 9A, a panel of representative microglia staining in the
spinal cord is shown. Cells were stained with Iba1 antibody.
Immunofluorescence staining for microglia revealed an increase
of Iba1-positive cells/optic field in the white matter anterior
fasciculus of EAE mice (247.66 ± 11.50). The results of the
quantitative measurements of microglia density are shown in
Figure 9B. 4a administration in EAE mice caused a reduction in
the number of Iba1 positive cells in the area evaluated that was,
at least in part, reverted by coadministration of 20 or 21
(Figure 9A,B).
Antinociceptive Effects of 4a in Animal Models of
Inflammatory and Neuropathic Pain. The in vivo antinoci-
ceptive profile of 4a was also evaluated in two different animal
models of pain. The compound inhibited both the first and
second phase of the nocifensive response to formalin in mice
(model of acute inflammatory pain). The maximum effect was
reached at the dose of 0.3 mg/kg (ip) (Figure 10A). MGL
inhibition may also produce therapeutic actions by impeding the
conversion of 2-AG into arachidonic acid and hence prosta-
glandins, thus acting in an endocannabinoid- andCBR-independent
manner.29 However, we found that the effect of 4a in the formalin
test was mediated by both CB1 and CB2 receptors because
both the selective CB1 antagonist/inverse agonist 20 and the
CB2 antagonist/inverse agonist 21 (each used at 1 mg/kg, ip),
administered 10 min prior to 4a, antagonized the antinociceptive
actions of the compound (Figure 10B). Importantly, 5 min after
the administration of 4a (0.3 mg/kg, ip), the levels of 2-AG in the
spinal cord and paw skin of mice coadministered with formalin,
measured by LC-MS, were found to be elevated (Table 4, see
Experimental Procedures for details). These results suggest that
compound 4a alleviates the pain behavior in the formalin test
by elevating endogenous 2-AG levels (Table 4), thus indirectly
activating both CB1 and CB2 receptors, as previously reported
for other MGL inhibitors.10
Next we evaluated the effect of 4a in a mouse model of
nociceptive behavior caused by the chemotherapeutic agent,
oxaliplatin (OXP, Figures 7C,D)30 (model of neuropathic pain
which is also a common symptom in MS patients). After oral
administration, the inhibitor dose-dependently reversed the
lowering of the threshold to cold stimuli (cold plate test) induced
by OXP, after acute administration on day 14 of OXP treat-
ment, when changes in pain thresholds were fully established
(Figure 10C). As shown in Figure 10D, 4amaintained its efficacy
after repeated treatments following a preventive protocol (daily
oral administration with OXP). Moreover, when subchronically
Figure 8.Myelin in the white matter of mice spinal cord. Luxol Fast Blue
staining shows areas of intact myelin (blue) and demyelination (pink).
Arrows indicate the demyelinated areas in EAE, EAE + 4a + 20 and
EAE + 4a + 21 groups. Scale bar: 100 μm.
Figure 9.Microglia positive cells in the white matter of mice spinal cord.
(A) Representative images of microglia cells stained with IBA1 (red)
and cell nuclei stained with DAPI (blue) in mice white matter of each
experimental group are shown. Scale bar: 100 μm. (B) Quantitative
measurements of the number of Iba1 positive cells in the white matter
spinal cord (anterior fasciculus). Statistical analysis. One-Way ANOVA
followed by Bonferroni comparison test: *** P < 0.001 vs control and
EAE + 4a; ∧∧P < 0.01 vs control, EAE + vehicle and EAE + 4a.
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administered, 4awas efficacious 24 h after the last administration.
These antinociceptive properties of 4a are related to conditions
of hypersensitivity, such as neuropathic pain, because 4a did not
modify normal pain thresholds evaluated in the hot-plate test
(Supporting Information, Table S1).
Collectively, the in vivo results are well consistent with the
theory that the endocannabinoid signalosome31 may play a
role in the modulation of the symptoms of MS32 as well as in
the molecular events underlying nociception, thus pointing to
selective inhibition of MGL as a potential strategy to produce
beneficial effects against the clinical outcomes of MS.
■ CONCLUSIONS
Combining bioinformatics and molecular modeling efforts we
generated an updated 3D pharmacophore model for the
development of selective hMGL inhibitors. Synthetic accessi-
bility, high potency and selectivity, and an interesting preliminary
pharmacokinetic profile, including low geno/cardio-toxicity,
characterize the novel β-lactam inhibitor 4a. We proved a stereo-
selective inhibition of MGL with the (3R,4S)-4a enantiomer
(Figure 3), being 70 times and 8 times more potent than 1 and its
distomer, respectively, against the human enzyme (4a IC50
hMGL = 4 nM vs 1 IC50 hMGL = 285 nM) (Table 1). The
mechanism of action (specific interaction with the catalytic
Ser122) was assessed by top-down and bottom-up proteomics
experiments while the high selectivity was assessed in binding
experiments on CBRs and on a proteome-based assay of
hydrolases including FAAH and ABHD (Figure 5). 4a lacks
mutagenic effect in the S. typhimurium strains TA98 and TA100
(Figure 6) and cardiotoxicity as assessed by ECG measurements
in Langendorff-isolated rat hearts. Additionally, 4a showed
favorable solubility, chemical stability at both neutral and
acidic pH, metabolic stability to hCYP3A4 and high permeability
Figure 10. In vivo antinociceptive effects of compound 4a. (A,B) Effect of compound 4a on formalin-induced acute pain in mice. The total time of the
nociceptive response was measured every 5 min and expressed in min (see Supporting Information). Data are means ± SEM from six mice and were
analyzed by one-way ANOVA followed by the Newman−Keuls’s post hoc test. (A) Effect of 4a administered ip 10 min before the injection of formalin
(1.25% in saline, 30 μL). Filled symbols denote statistically significant differences vs formalin (P < 0.05). In (B) the selective CB1 inverse agonist 20 or
the CB2 inverse agonist 21 were injected ip 10 min before 4a. (C,D) Effect of 4a on OXP-induced neuropathic pain. On day 14 of OXP administration
(2.4 mg/kg ip daily), the response to a thermal stimulus was evaluated by the cold plate test measuring the latency to pain-related behavior (lifting or
licking of the paw). (C) Acute effect of 4awas evaluated after a single po administration (time 0) over time. (D) Subchronic effect of 4awas observed on
day 14 after repeated administrations (daily starting from the first day of OXP treatment), and the measurement was performed 24 h after the last
administration. ̂P̂ < 0.01 respect to the value before treatment (0); **P < 0.01 in comparison to vehicle + vehicle;
§§P < 0.01 in comparison to OXP +
vehicle. Each value is the mean of 12 mice.
Table 4. 2-AG Tissue Levels in Formalin Treated Mice
Administered (ip) with 4a
2-AG (pmol/g)a
vehicle/saline 4a/saline vehicle/formalin 4a/formalin
spinal cord 6.4 ± 0.4 9.7 ± 1.3 3.8 ± 0.4 6.6 ± 0.7b
paw skin 6.1 ± 0.3 11.0 ± 2.8 10.8 ± 1.5 14.1 ± 1.6b
aMeans ± SEM, n = 4, analyzed by ANOVA + Bonferroni’s posthoc
test. bP < 0.05 vs vehicle/formalin.
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through artificial membranes, and high brain penetration. Anti-
nociceptive effects on inflammatory and neuropathic pain animal
models were assessed after oral and ip administration of 4a. After
ip administration of 0.3 mg/kg, a marked analgesic action was
registered, with inhibition of both the first and second phase of
the nocifensive response to formalin. Oral administration of 4a
already at 1mg/kg dose dependently reversed the lowering of the
threshold to cold stimuli (cold plate test) induced by OXP,
indicating its efficacy in the treatment of neuropathic pain.
In vivo experiments evidenced a clear-cut dependence of the pain
reliever profile of 4a from endocannabinoid system activation
(Figure 7). 4a was also tested on the EAE animal model
(ip administration, Figure 8), 4a elicited a striking beneficial
effect on disease progression that could involve both CB1- and
CB2-mediated signaling. Interestingly, in animals administered
with either CBR antagonists/inverse agonists (20 and 21),
the seriousness of the clinical symptoms was delayed when
compared to control EAE mice, reaching however a maximum
clinical score (at 21 dpi) that was comparable to that detected in
untreated EAE mice (at 17 dpi). In line with these data, in EAE
mice treated with 4a, the histological evaluation of myelin, by
Luxol Fast Blue staining, demonstrated a significant reduction of
the demyelinated areas which was partially counteracted by
the coadministration of 20 and 21 (Figure 8). Notably these
outcomes were paralleled by those obtained when looking at
microglia because 4a decreased the number of Iba1 positive cells,
an effect that is in part prevented by coadministration of 20 or 21
(Figure 9). Because EAE is a disease model widely applied
to study MS, these data could suggest MGL inhibition as an
innovative therapeutic approach for treating MS symptoms.
■ EXPERIMENTAL SECTION
Chemistry. Unless otherwise specified, materials were purchased
from commercial suppliers and used without further purification.
Reaction progress was monitored by TLC using silica gel 60 F254
(0.040−0.063 mm) with detection by UV. Silica gel 60 (0.040−
0.063 mm) or aluminum oxide 90 (0.063−0.200 mm) were used for
column chromatography. 1H NMR and 13C NMR spectra were
recorded on a Varian 300 MHz spectrometer by using the residual
signal of the deuterated solvent as internal standard. Splitting patterns
are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet
(p), and broad (br); the value of chemical shifts (δ) are given in ppm and
coupling constants (J) in hertz (Hz). ESI-MS spectra were performed by
an Agilent 1100 series LC/MSD spectrometer. Melting points were
determined in Pyrex capillary tubes using an Electrothermal 8103
apparatus and are uncorrected. Optical rotation values were measured at
room temperature using a PerkinElmer model 343 polarimeter operat-
ing at = 589 nm, corresponding to the sodium D line. Yields refer to
purified products and are not optimized. All moisture-sensitive reactions
were performed under argon atmosphere using oven-dried glassware
and anhydrous solvents. ESI-MS spectra for exact mass determination
were performed on a LTQ Orbitrap Thermo Fischer Scientific instru-
ment. All final compounds were purified by flash column chromatog-
raphy, and the purity of all compounds tested was ≥ 95% as determined
by elemental analysis. Elemental analyses were performed in a
PerkinElmer 240C elemental analyzer, and the results were within
± 0.4% of the theoretical values unless otherwise noted.
Experimental Procedures. trans-(1-(1-(1H-1,2,4-Triazole-1-
carbonyl)piperidin-4-yl)-4-benzo[d][1,3]dioxol-5-yl)-3-(4-
fluorophenyl)azetidin-2-one ((±)-4a).Toa solution of 1H-1,2,4-triazole
(15 mg, 0.22 mmol) in dry dichloromethane (10.0 mL), phosgene 20%
solution in toluene (115 μL, 0.22 mmol) and DMAP (55 mg, 0.44 mmol)
were added and themixture was stirred at 25 °C for 1 h. Then a solution of
amine (±)-6a (40 mg, 0.11 mmol) in dry dichloromethane (5.0 mL) was
added and the reaction was stirred at 25 °C for 12 h. The solvent was
removed under reduced pressure. The crude was purified by means of
chromatography on silica gel (1:1 ethyl acetate/n-hexane) to afford
compound (±)-4a (30 mg, 60% yield) as a white solid. 1H NMR
(300MHz, CDCl3) δ 8.75 (s, 1H), 7.97 (s, 1H), 7.20 (m, 2H), 7.03 (t, J =
8.6 Hz, 2H), 6.87 (s, J = 7.8 Hz, 1H), 6.82 (d, J = 0.7 Hz, 2H), 6.01 (d, J =
1.4 Hz, 2H), 4.50 (m, 2H), 4.38 (d, J = 2.3 Hz, 1H), 4.08 (d, J = 2.1 Hz,
1H), 3.78 (m, 1H), 3.13 (m, 2H), 2.07 (m, 2H), 1.89 (dd, J = 13.4, 3.2 Hz,
1H), 1.63 (qd, J = 11.5, 4.1 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ
168.4, 162.5 (d, JC−F = 246.6 Hz), 152.3, 148.9, 148.6, 148.5, 146.9,
132.0, 130.8 (d, JC−F = 3.3 Hz), 129.1 (d, JC−F = 8.1 Hz), 120.6, 116.1
(d, JC−F = 21.6 Hz), 108.9, 106.2, 101.7, 64.0, 63.4, 50.7, 45.5 (2C), 30.4,
30.1. ESI-MS m/z: 464 [M + H]+, 486 [M + Na]+. HRMS (ESI) m/z
[M + H]+ calcd for C24H22FN5O4 464.1729, found 464.1731, [M + Na]
+;
calcd for C24H22FN5O4 486.1548, found 486.1551; [M + K]
+ calcd for








(−)-4a). 1H NMR and 13C NMR are identical to those reported for
(±)-4a.
4-Nitrophenyl-4-((trans-2-(benzo[d][1,3]dioxol-5-yl)-3-(4-fluoro-
phenyl)-4-oxoazetidin-1-yl)piperidine-1-carboxylate (4b). To a
stirred solution of (±)-6a (40 mg, 0.11 mmol) in dry dichloromethane
(15.0 mL), 4-nitrophenyl chloroformate (33 mg, 0.17 mmol) and TEA
(45 μL, 0.33 mmol) were added and the mixture was stirred at 25 °C
under Ar atmosphere for 12 h. The solvent was removed under reduced
pressure. The crude was purified by means of chromatography on silica
gel (1:4 ethyl acetate/n-hexane) to afford title compound (30 mg, 52%
yield) as an amorphous white solid. 1H NMR (300MHz, CDCl3) δ 8.24
(d, J = 8.9 Hz, 2H), 7.42−7.15 (m, 4H), 7.05 (t, J = 8.5 Hz, 2H), 6.90 (s,
1H), 6.84 (s, 2H), 6.03 (s, 2H), 4.40 (br s, 1H), 4.37−4.02 (m, 3H), 3.71
(m, 1H), 3.24−2.79 (m, 2H), 2.23−1.74 (m, 3H), 1.57 (m, 1H). 13C
NMR (75 MHz, CDCl3) δ 168.4, 162.5 (d, JC−F = 246.6 Hz), 156.3,
152.3, 148.9, 148.6, 145.1, 132.2, 130.9 (d, JC−F = 3.0 Hz), 129.1 (d,
JC−F = 8.1 Hz), 125.3, 122.5, 120.7, 116.2 (d, JC−F = 21.6 Hz), 109.0,
106.3, 101.8, 63.9, 63.5, 50.8, 43.8 (2C), 30.2 (2C). ESI-MS m/z: 534
[M + H]+. Anal. (C28H24FN3O7) C, H, N.
trans-1-(1-(1H-Imidazole-1-carbonyl)piperidin-4-yl)-4-(benzo[d]-
[1,3]dioxol-5-yl)-3-(4-fluorophenyl)azetidin-2-one (4c). To a solution
of (±)-6a (40 mg, 0.11 mmol) in dry dichloromethane (15.0 mL), 1,1-
carbonyldiimidazole (35 mg, 0.22 mmol) was added and the mixture
was stirred at 25 °C for 12 h. The solvent was removed under reduced
pressure. The crude was purified by means of chromatography on silica
gel (1:1 ethyl acetate/n-hexane) to afford title compound (20 mg, 40%
yield) as an amorphous white solid. 1H NMR (300MHz, CDCl3) δ 7.82
(s, 1H), 7.21 (m, 2H), 7.15 (s, 1H), 7.06 (m, 3H), 6.88 (d, J = 1.0 Hz,
1H), 6.83 (d, J = 1.2 Hz, 2H), 6.03 (s, 2H), 4.38 (d, J = 2.2 Hz, 1H), 4.09
(m, 3H), 3.73 (m, 1H), 3.23−3.01 (m, 2H), 2.07 (m, 2H), 1.89 (m, 1H),
1.59 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 168.4, 162.5 (d, JC−F =
246.7 Hz), 151.0, 149.0, 148.6, 137.1, 131.9, 130.7 (d, JC−F = 3.2 Hz),
129.9, 129.0 (d, JC−F = 8.1 Hz), 120.6, 118.2, 116.2 (d, JC−F = 21.5 Hz),
109.0, 106.2, 101.8, 63.9, 63.5, 50.6, 45.6, 45.4, 30.4, 30.1. ESI-MS m/z:
463 [M + H]+, 485 [M + Na]+. Anal. (C25H23FN4O4) C, H, N.
1,1,1,3,3,3-Hexafluoropropan-2-yl-4-(2-(benzo[d][1,3]dioxol-5-
yl)-3-(4-fluorophenyl)-4-oxoazetidin-1-yl)piperidine-1-carboxylate
(4d). To a stirred solution of 1,1,1,3,3,3-hexafluoroisopropanol (13 mg,
0.08 mmol) in dry dichloromethane (5.0 mL), triphosgene (12 mg,
0.04 mmol) and DIPEA (30 μL, 0.16 mmol) were added and the
mixture was stirred at rt under Ar atmosphere for 30 min. Then, a
solution of (±)-6a (25 mg, 0.07 mmol) in dry dichloromethane
(2.5 mL) was added and the mixture was stirred at rt for 12 h. The
solvent was removed under reduced pressure, and the crude was purified
by means of flash chromatography (1:2 ethyl acetate/n-hexane) to
afford title compound (11 mg, 30% yield) as colorless oil. 1H NMR
(300 MHz, CDCl3) δ 7.22 (m, 2H), 7.04 (m, 2H), 6.87 (d, J = 1.0 Hz,
1H), 6.82 (d, J = 1.1 Hz, 2H), 6.02 (s, 2H), 5.70 (p, J = 6.2 Hz, 1H), 4.36
(d, J = 2.3 Hz, 1H), 4.26−3.90 (m, 3H), 3.66 (m, 1H), 2.92 (m, 2H),
2.14−1.98 (m, 1H), 1.93 (m, 2H), 1.51 (m, 1H). 13C NMR (75 MHz,
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CDCl3) δ 168.3, 162.50 (d, JC−F = 246.8 Hz), 151.5, 148.9, 148.6, 132.0,
130.8 (d, JC−F = 3.3 Hz), 129.0 (d, JC−F = 8.1 Hz), 120.8 (d, JC−F =
283.3 Hz), 120.6, 116.2 (d, JC−F = 21.6 Hz), 108.9, 106.2, 101.7, 68.4,
63.9, 63.43, 50.5, 44.0, 43.4, 30.0 (2C). ESI-MSm/z: 563 [M +H]+, 585
[M + Na]+. Anal. (C25H21F7N2O5) C, H, N.
trans-1-(1-(1H-1,2,4-Triazole-1-carbonyl)piperidin-4-yl)-4-
(benzo[d][1,3]dioxol-5-yl)-3-(4-methoxyphenyl)azetidin-2-one (4e).
Title compound was obtained starting from 6b as described for
compound (±)-4a. The crude was purified bymeans of chromatography
on silica gel (1:1 ethyl acetate/n-hexane) to afford pure title compound
(30 mg, 57% yield) as an amorphous white solid. 1H NMR (300 MHz,
CDCl3) δ 8.76 (s, 1H), 7.98 (s, 1H), 7.15 (d, J = 7.1 Hz, 2H), 6.90 (m,
3H), 6.82 (s, 2H), 6.02 (s, 2H), 4.70−4.27 (m, 3H), 4.05 (br s, 1H), 3.79
(m, 4H), 3.15 (m, 2H), 2.09 (m, 2H), 1.90 (d, J = 12.3 Hz, 1H), 1.66 (m,
1H). 13C NMR (75 MHz, CDCl3) δ 169.1, 159.4, 152.4, 148.8, 148.7,
148.4, 132.4, 128.6, 127.1, 120.6, 114.6, 108.9, 106.3, 101.7, 64.3, 63.7,
55.6, 50.6, 45.4, 30.4, 30.2. ESI-MSm/z: 476 [M + H]+, 498 [M +Na]+.
Anal. (C25H25N5O5) C, H, N.
trans-1-(1-(1H-1,2,4-Triazole-1-carbonyl)piperidin-4-yl)-4-(3,4-di-
methoxyphenyl)-3-(4-methoxyphenyl)azetidin-2-one (4f).Title com-
poundwas obtained starting from 6c as described for compound (±)-4a.
The crude was purified by means of chromatography on silica gel (1:1
ethyl acetate/n-hexane) to afford title compound (25 mg, 52% yield) as
an amorphous white solid. 1H NMR (300 MHz, CDCl3) δ 8.74 (s, 1H),
7.96 (s, 1H), 7.16 (d, J = 8.3 Hz, 2H), 6.97−6.78 (m, 5H), 4.70−4.29
(m, 3H), 4.09 (br s, 1H), 3.89 (s, 6H), 3.84−3.72 (m, 4H), 3.13 (m,
2H), 2.11 (m, 2H), 1.87 (dd, J = 13.3, 3.0 Hz, 1H), 1.62 (qd, J = 12.0,
4.0 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 169.3, 159.4, 152.3, 149.9,
149.8, 148.6, 146.9, 130.9, 128.6, 127.2, 119.4, 114.7, 111.6, 109.0, 64.2,
63.8, 56.3, 56.2, 55.6, 50.6, 45.4, 30.4, 30.2. ESI-MSm/z: 492 [M + H]+,
514 [M + Na]+. Anal. (C26H29N5O5) C, H, N.
trans-1-(1-(1H-1,2,4-Triazole-1-carbonyl)piperidin-4-yl)-3,4-bis-
(3,4-dimethoxyphenyl)azetidin-2-one (4g). Title compound was
obtained starting from 6d as described for compound (±)-4a. The
crude was purified by means of chromatography on silica gel (1:1 ethyl
acetate/n-hexane) to afford title compound (20 mg, 45% yield) as an
amorphous white solid. 1H NMR (300 MHz, CDCl3) δ 8.76 (s, 1H),
7.98 (s, 1H), 7.03−6.79 (m, 5H), 6.75 (s, 1H), 4.71−4.33 (m, 3H), 4.11
(d, J = 1.7 Hz, 1H), 3.99−3.73 (m, 13H), 3.15 (m, 2H), 2.11 (m, 2H),
1.88 (m, 1H), 1.66 (m, 1H). 13CNMR (75MHz, CDCl3) δ 169.1, 152.3,
150.0, 149.8, 149.5, 148.9, 148.7, 130.9, 127.6, 119.5, 111.0, 111.7, 110.8,
108.9, 64.5, 63.8, 56.3, 56.2, 56.2, 50.6, 45.3, 30.4, 30.2. ESI-MSm/z: 522
[M + H]+, 544 [M + Na]+. Anal. (C27H31N5O6) C, H, N.
trans-1-(1-(1H-1,2,4-Triazole-1-carbonyl)piperidin-4-yl)-3,4-bis(4-
methoxyphenyl)azetidin-2-one (4h). Title compound was obtained
starting from 6d as described for compound (±)-4a. The crude was
purified by means of chromatography on silica gel (1:1 ethyl acetate/
n-hexane) to afford title compound (24mg, 47% yield) as an amorphous
white solid. 1H NMR (300 MHz, CDCl3) δ 8.74 (s, 1H), 7.97 (s, 1H),
7.30 (m, 2H), 7.15 (d, J = 8.7 Hz, 2H), 6.99−6.78 (m, 4H), 4.76−4.30
(m, 3H), 4.07 (d, J = 2.1 Hz, 1H), 3.83−3.67 (m, 7H), 3.1 (m, 2H), 2.09
(m, 2H), 1.85 (dd, J = 13.2, 3.5 Hz, 1H), 1.61 (m, 1H). 13C NMR
(75 MHz, CDCl3) δ 169.2, 160.3, 159.4, 152.2, 148.6, 146.9, 130.4,
128.6, 127.9, 127.2, 114.8, 114.6, 64.3, 63.4, 55.6, 55.5, 50.5, 45.5, 30.4,
30.2. ESI-MS m/z: 462 [M + H]+, 484 [M + Na]+. Anal. (C25H27N5O4)
C, H, N.
trans-4-(Benzo[d][1,3]dioxol-5-yl)-1-(1-benzylpiperidin-4-yl)-3-(4-
fluorophenyl)azetidin-2-one ((±)-5a). A solution of 4-fluorophenyl-
acetic acid (385 mg, 2.49 mmol) and triphosgene (245 mg, 0.83 mmol)
in dry dichloromethane (15.0 mL) was heated at 50 °C for 30min. Then
a solution of imine 11a (1.66 mmol) in dry dichloromethane (5.0 mL)
was added dropwise, followed by the addition of TEA (695 μL,
4.98 mmol), and the mixture was heated at 50 °C for 12 h. The solvent
was removed under reduced pressure. The crude was purified by means
of flash chromatography on silica gel (1:2 ethyl acetate/n-hexane) to
afford compound 5a (460 mg, 61% yield) as a pale-yellow oil. 1H NMR
(300 MHz, CDCl3) δ 7.24 (m, 7H), 7.02 (t, J = 8.6 Hz, 2H), 6.89
(s, 1H), 6.81 (m, 2H), 5.98 (s, 2H), 4.37 (d, J = 2.2 Hz, 1H), 4.02 (d, J =
1.6Hz, 1H), 3.58 (m, 1H), 3.44 (s, 2H), 2.83 (dd, J = 34.7, 11.2 Hz, 2H),
1.98 (m, 4H), 1.71 (dd, J = 12.6, 2.9 Hz, 1H), 1.52 (qd, J = 11.9, 3.9 Hz,
1H). 13C NMR (75 MHz, CDCl3) δ 168.4, 162.6 (d, JC−F = 246.3 Hz),
148.7, 148.3, 138.4, 132.9, 131.3 (d, JC−F = 3.2 Hz), 129.3, 129.2 (d,
JC−F = 8.1 Hz), 128.4, 127.3, 120.5, 116.1 (d, JC−F = 21.5 Hz), 108.8,
106.4, 101.6, 63.9, 63.3, 63.2, 52.6, 52.40, 51.3, 30.7, 30.4. ESI-MS m/z:
459 [M + H]+, 481 [M + Na]+. Anal. (C28H27FN2O3) C, H, N.
trans-4-(Benzo[d][1,3]dioxol-5-yl)-1-(1-benzylpiperidin-4-yl)-3-(4-
methoxyphenyl)azetidin-2-one (5b). Starting from 4-methoxylphenyl-
acetic acid (415 mg, 2.49 mmol) and imine 11a (1.66 mmol), the title
compound was obtained following the same procedure reported for
(±)-5a. The crude was purified by means of flash chromatography on
silica gel (1:2 ethyl acetate/n-hexane) to afford title compound (500 mg,
64% yield) as a pale-yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (m,
5H), 7.16 (m, 2H), 6.88 (m, 3H), 6.80 (m, 2H), 5.99 (s, 2H), 4.36 (d, J =
2.2 Hz, 1H), 3.97 (d, J = 2.1 Hz, 1H), 3.77 (s, 3H), 3.59 (m, 1H), 3.44 (s,
2H), 2.83 (m, 2H), 2.01 (m, 4H), 1.70 (dd, J = 12.7, 2.8 Hz, 1H), 1.52
(qd, J = 11.6, 3.9 Hz, 1H). ESI-MS m/z: 471 [M + H]+, 493 [M + Na]+.
trans-1-(1-Benzylpiperidin-4-yl)-4-(3,4-dimethoxyphenyl)-3-(4-
methoxyphenyl)azetidin-2-one (5c). Starting from 4-methoxyphenyl-
acetic acid (415 mg, 2.49 mmol) and imine 11b (1.66 mmol), the title
compound was obtained following the same procedure reported for
(±)-5a. The crude was purified by means of flash chromatography on
silica gel (1:2 ethyl acetate/n-hexane) to afford title compound (440 mg,
54% yield) as a pale-yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.24 (m,
5H), 7.15 (m, 2H), 6.89 (m, 5H), 4.38 (d, J = 2.2 Hz, 1H), 4.01 (d, J =
2.1 Hz, 1H), 3.86 (s, 6H), 3.75 (s, 3H), 3.60 (m, 1H), 3.41 (s, 2H), 2.80
(dd, J = 36.3, 9.4 Hz, 2H), 1.98 (m, 4H), 1.68 (dd, J = 12.3, 2.4 Hz, 1H),
1.50 (qd, J = 11.8, 3.7 Hz, 1H). ESI-MS m/z: 487 [M + H]+, 509
[M + Na]+.
trans-1-(1-Benzylpiperidin-4-yl)-3,4-bis(3,4-dimethoxyphenyl)-
azetidin-2-one (5d). Starting from 3,4-dimethoxyphenylacetic acid
(490 mg, 2.49 mmol) and imine 11b (1.66 mmol), the title compound
was obtained following the same procedure reported for (±)-5a. The
crude was purified by means of flash-chromatography on silica gel (1:2
ethyl acetate/n-hexane) to afford title compound (385mg, 45% yield) as
pale-yellow oil. 1HNMR (300MHz, CDCl3) δ 7.25 (m, 5H), 7.02−6.61
(m, 6H), 4.40 (d, J = 2.1 Hz, 1H), 4.01 (d, J = 2.1 Hz, 1H), 3.88 (s, 6H),
3.83 (s, 6H), 3.62 (m, 1H), 3.43 (m, 2H), 2.97 (dd, J = 12.6, 1.7 Hz, 1H),
2.81 (dd, J = 37.6, 10.3 Hz, 1H), 1.99 (m, 4H), 1.68 (d, J = 10.6 Hz, 1H),
1.50 (qd, J = 11.5, 2.7 Hz, 1H). ESI-MS m/z: 517 [M + H]+, 539
[M + Na]+.
trans-1-(1-Benzylpiperidin-4-yl)-3,4-bis(4-methoxyphenyl)-
azetidin-2-one (5e). Starting from 4-methoxyphenylacetic acid
(415 mg, 2.49 mmol) and imine 11c (1.66 mmol), the title compound
was obtained following the same procedure reported for (±)-5a. The
crude was purified by means of flash-chromatography on silica gel (1:2
ethyl acetate/n-hexane) to afford title compound (440mg, 59% yield) as
a pale-yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.35−7.21 (m, 7H),
7.13 (m, 2H), 6.88 (m, 4H), 4.39 (d, J = 2.0 Hz, 1H), 3.99 (d, J = 2.0 Hz,
1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.59 (m, 1H), 3.43 (s, 2H), 2.81 (m,
2H), 2.00 (m, 4H), 1.65 (dd, J = 12.6, 3.1 Hz, 1H), 1.45 (qd, J = 12.0,
3.9 Hz, 1H). ESI-MS m/z: 457 [M + H]+.
trans-4-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)-1-(piperi-
din-4-yl)azetidin-2-one ((±)-6a). To a solution of (±)-5a (100 mg,
0.22mmol) inmethanol (25.0mL), a catalytic amount of Pd/C 10%was
added and the mixture was stirred under hydrogen atmosphere at 1 atm
for 2 h. Then Pd/C was filtered off and the solvent was removed under
reduced pressure. The crude transparent oil (quantitative yield) was
used in the following step without any further purification. 1H NMR
(300 MHz, CD3OD) δ 7.30 (m, 2H), 7.11 (m, 2H), 7.01 (s, 1H), 6.96
(d, J = 8.0 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 5.98 (s, 2H), 4.65 (d, J =
2.1 Hz, 1H), 4.19 (d, J = 1.8 Hz, 1H), 3.72 (m, 1H), 3.41 (m, 2H), 3.31
(m, 1H), 3.03 (m, 2H), 2.21 (m, 2H), 2.09 (dd, J = 14.1, 3.5 Hz, 1H),
1.87 (qd, J = 11.6, 4.0 Hz, 1H). 13C NMR (75 MHz, CD3OD) δ 169.5,
162.6 (d, JC−F = 245.1 Hz), 148.9, 148.6, 131.7, 131.0 (d, JC−F = 3.2 Hz),
129.3 (d, JC−F = 8.2 Hz), 120.1, 115.6 (d, JC−F = 21.8 Hz), 108.5, 106.4,
101.7, 63.3, 42.8, 42.7, 27.1, 26.7. ESI-MS m/z: 369 [M + H]+. Anal.
(C21H21FN2O3) C, H, N.
trans-4-(Benzo[d][1,3]dioxol-5-yl)-3-(4-methoxyphenyl)-1-(piperi-
din-4-yl)azetidin-2-one (6b). Starting from 5b (100 mg, 0.21 mmol),
title compound was obtained following the same procedure used for
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(±)-6a. 1H NMR (300 MHz, CDCl3) δ 7.15 (d, J = 8.4 Hz, 2H), 6.86
(m, 3H), 6.78 (m, 2H), 5.99 (s, 2H), 4.37 (d, J = 1.9Hz, 1H), 4.00 (d, J =
1.7 Hz, 1H), 3.79 (s, 3H), 3.67 (m, 1H), 3.05 (m, 2H), 2.58 (m, 2H),
1.86 (m, 4H), 1.37 (qd, J = 12.3, 4.2 Hz, 1H). ESI-MS m/z: 381 [M +
H]+.
trans-4-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)-1-(piperi-
din-4-yl)azetidin-2-one (6c). Starting from 5c (100 mg, 0.21 mmol),
title compound was obtained following the same procedure used for
(±)-6a. 1H NMR (300 MHz, CDCl3) δ 7.15 (d, J = 8.6 Hz, 2H), 6.87
(m, 5H), 4.39 (d, J = 2.2 Hz, 1H), 4.03 (d, J = 2.0 Hz, 1H), 3.88 (s, 6H),
3.77 (s, 3H), 3.67 (m, 1H), 3.03 (m, 2H), 2.56 (m, 2H), 1.83 (m, 4H),
1.35 (qd, J = 12.1, 4.1 Hz, 1H). ESI-MS m/z: 397 [M + H]+.
trans-3,4-Bis(3,4-dimethoxyphenyl)-1-(piperidin-4-yl)azetidin-2-
one (6d). Starting from 5d (100 mg, 0.19 mmol), title compound was
obtained following the same procedure used for (±)-6a. 1H NMR
(300 MHz, CDCl3) δ 7.06−6.62 (m, 6H), 4.41 (d, J = 2.3 Hz, 1H), 4.04
(d, J = 1.9 Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H),
3.68 (m, 1H), 2.97 (m, 2H), 2.58 (m, 2H), 1.87 (m, 4H), 1.39 (m, 1H).
ESI-MS m/z: 427 [M + H]+.
trans-3,4-Bis(4-methoxyphenyl)-1-(piperidin-4-yl)azetidin-2-one
(6e). Starting from 5e (100 mg, 0.22 mmol), title compound was
obtained following the same procedure used for (±)-6a. 1H NMR
(300 MHz, CDCl3) δ 7.28 (m, 2H), 7.15 (d, J = 8.4 Hz, 2H), 6.88 (m,
4H), 4.40 (d, J = 1.9 Hz, 1H), 4.02 (d, J = 1.7 Hz, 1H), 3.82 (s, 3H), 3.78
(s, 3H), 3.67 (m, 1H), 3.02 (m, 2H), 2.56 (m, 2H), 1.82 (m, 4H), 1.32
(m, 1H). ESI-MS m/z: 367 [M + H]+.
(4-((2S,3S)-2-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)-
azetidin-1-yl)piperidin-1-yl)(1H-1,2,4-triazol-1-yl)methanone
((±)-7). Starting from 1H-1,2,4-triazole (32 mg, 0.46 mmol) and com-
pound (±)-13 (80 mg, 0.23 mmol), the title compound was obtained
following the same procedure reported for (±)-4a. The crude was
purified bymeans of flash chromatography (dichloromethane/methanol
10:1) to afford pure compound (±)-7 as a transparent oil (yield). 1H
NMR (300 MHz, CDCl3) δ 8.73 (s, 1H), 7.97 (s, 1H), 7.09 (m, 2H),
6.97 (t, J = 8.4Hz, 2H), 6.64 (d, J = 7.8Hz, 1H), 6.52 (s, 1H), 6.45 (d, J =
7.8 Hz, 1H), 5.89 (s, 2H), 4.32 (br s, 1H), 3.30−2.52 (m, 8H), 1.88 (d,
J = 11.6 Hz, 2H), 1.46−1.26 (m, 2H). ESI-MSm/z: 450 [M +H]+. Anal.
(C24H24FN5O3) C, H, N.
trans-4-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)azetidin-2-
one ((±)-8). To a stirred solution of compound (±)-18 (50 mg,
0.11 mmol) in dry tetrahydrofuran (1.0 mL), a 0.1 N solution of SmI2 in
tetrahydrofuran (6.6 mL, 0.66 mmol) was added and the reaction was
stirred at 25 °C under Ar atmosphere for 15 min. A saturated solution of
NaHCO3 was added, and the aqueous phase was extracted with ethyl
acetate (3 × 10.0 mL).The combined organic layers were dried over
Na2SO4, filtered, and evaporated. The crude was purified by means of
flash-chromatography on silica gel (1:2 ethyl acetate/n-hexane) to afford
pure compound (±)-8 (20 mg, 65% yield) as a white solid. 1H NMR
(300MHz, CDCl3) δ 7.33−7.18 (m, 2H), 7.03 (t, J = 8.5Hz, 2H), 6.93−
6.67 (m, 3H), 6.44 (s, 1H), 5.97 (s, 2H), 4.51 (d, J = 2.4 Hz, 1H), 4.10
(d, J = 2.4 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 168.9, 162.5 (d,
JC−F = 246.6 Hz), 148.7, 148.1, 133.4, 130.7 (d, JC−F = 3.3 Hz), 129.2
(d, JC−F = 8.1 Hz), 119.4, 116.1 (d, JC−F = 21.6 Hz), 108.8, 105.9, 101.6,
65.8, 60.5. ESI-MS m/z: 286 [M + H]+, 308 [M + Na]+. Anal.
(C16H12FNO3) C, H, N.
Piperidin-1-yl(1H-1,2,4-triazol-1-yl)methanone (9). To a solution
of 1H-1,2,4-triazole (325 mg, 4.70 mmol) in dry dichloromethane
(20.0 mL), phosgene 20% solution in toluene (2.3 mL, 4.70 mmol) and
4-(dimethylamino)pyridine (1.15 g, 9.4 mmol) were added and the
mixture was stirred at 25 °C for 1 h. Then a solution of piperidine (19,
230 μL, 2.35 mmol) in dry dichloromethane (5.0 mL) was added and
the reaction was stirred under Ar atmosphere for 12 h. The solvent was
removed under reduced pressure. The crude was purified by means of
chromatography on silica gel (1:1 ethyl acetate/n-hexane) to afford
compound 9 (quantitative yield) as a yellow oil. 1H NMR (300 MHz,
CDCl3) δ 8.75 (s, 1H), 7.99 (s, 1H), 3.74 (br s, 4H), 1.71 (br s, 6H).
ESI-MS m/z: 219 [M + K]+. Anal. (C8H12N4O) C, H, N.
N-(Benzo[d][1,3]dioxol-5-ylmethylene)-1-benzylpiperidin-4-
amine (11a). A solution of 4-amino-1-benzylpiperidine (340 μL,
1.66 mmol) and (3,4-methylendioxy)benzaldehyde (10a) (250 mg,
1.66 mmol) in absolute ethanol (25.0 mL) was heated at 80 °C for 12 h.
The mixture was cooled to rt, and the solvent was removed under
reduced pressure. The crude imine (quantitative yield) was used in
the following step without any further purification. ESI-MS m/z: 323
[M + H]+.
N-(3,4-Dimethoxybenzylidene)-1-benzylpiperidin-4-amine (11b).
Starting from 4-amino-1-benzylpiperidine (340 μL, 1.66 mmol) and 3,4-
dimethoxybenzaldehyde (10b, 275 mg, 1.66 mmol), the title compound
was obtained following the same procedure reported for 11a. ESI-MS
m/z: 339 [M + H]+.
N-(4-Methoxybenzylidene)-1-benzylpiperidin-4-amine (11c).
Starting from 4-amino-1-benzylpiperidine (340 μL, 1.66 mmol) and
4-methoxybenzaldehyde (11c, 200 μL, 1.66 mmol), the title compound
was obtained following the same procedure reported for 11a. ESI-MS
m/z: 309 [M + H]+.
4-(trans-2-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)azetidin-
1-yl)-1-benzylpiperidine ((±)-12). To a stirred suspension of AlCl3
(205 mg, 1.54 mmol) in dry diethyl ether, cooled to 0 °C, a suspension
of LiAlH4 (97.0 mg, 2.6 mL) in dry tetrahydrofuran was added and the
mixture was stirred for 1 h under Ar atmosphere. Then (±)-5a (200 mg,
0.44 mmol) dissolved in dry tetrahydrofuran was added dropwise and
the mixture was stirred for 45 min before adding a solution of NaOH
10% in water (1.0 mL). The reaction was stirred for further 30 min at
0 °C. The aqueous phase was extracted with ethyl acetate (3× 10.0 mL),
and the combined organic layers were dried over Na2SO4, filtered, and
evaporated. The crude was purified by means of flash chromatography
on silica gel (1:2 ethyl acetate/n-hexane) to afford compound (±)-12
(110 mg, 56% yield) as a yellow oil. 1H NMR (300MHz, CDCl3) δ 7.31
(m, 5H), 7.14 (m, 2H), 7.06 (s, 1H), 6.98 (t, J = 8.5 Hz, 2H), 6.76 (dd,
J = 28.8, 7.9 Hz, 2H), 5.93 (s, 2H), 3.88 (d, J = 8.0 Hz, 1H), 3.78 (t, J =
6.8 Hz, 1H), 3.47 (q, J = 13.2 Hz, 2H), 3.34 (dd, J = 16.3, 8.1 Hz, 1H),
2.97 (m, 1H), 2.86 (d, J = 11.1 Hz, 1H), 2.67 (d, J = 11.1 Hz, 1H), 2.26
(t, J = 9.7 Hz, 1H), 2.05 (t, J = 10.8 Hz, 1H), 1.90 (t, J = 10.9 Hz, 1H),
1.77 (d, J = 12.2 Hz, 1H), 1.49 (dd, J = 23.8, 11.5 Hz, 2H), 1.23 (m, 1H).
ESI-MS m/z: 445 [M + H]+.
4-(trans-2-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)azetidin-
1-yl)piperidine ((±)-13). Starting from compound (±)-12 (110 mg,
0.25 mmol), the title compound was obtained following the same
procedure reported for (±)-6a. The crude transparent oil (quantitative
yield) was used in the following step without any further purification. 1H
NMR (300 MHz, CDCl3) δ 7.05 (m, 2H), 6.96 (m, 2H), 6.60 (d, J =
7.9 Hz, 1H), 6.50 (d, J = 1.3 Hz, 1H), 6.45 (m, 1H), 5.88 (s, 2H), 3.15−
2.53 (m, 7H), 2.45−2.25 (m, 1H), 2.23−2.19 (m, 1H), 2.07−1.81
(m, 2H), 1.81−1.59 (m, 1H), 1.40−0.99 (m, 2H). ESI-MS m/z: 393
[M + K]+.
3-(Benzo[d]thiazol-2-ylamino)propan-1-ol (15). To a stirred
solution of 2-chlorobenzothiazole (14, 790 μL, 6.05 mmol) in
chlorobenzene (20.0 mL), 3-amino-1-propanol (510 μL, 6.66 mmol)
and DIPEA (4.2 mL, 24.20 mmol) were added and the mixture was
stirred at 130 °C under Ar atmosphere for 4 h. The reaction was cooled
to 25 °C, and the solvent was removed under reduce pressure.Water was
added, and the aqueous phase was extracted with ethyl acetate (3 ×
15.0 mL). The combined organic layers were dried over Na2SO4,
filtered, and evaporated. Crude title compoundwas used in the following
step without any further purification (1.02 g, 81% yield). 1H NMR
(300 MHz, CDCl3) δ 7.53 (t, J = 8.6 Hz, 1H), 7.30 (dd, J = 7.4, 1.2 Hz,
1H), 7.09 (t, J = 7.6 Hz, 1H), 5.46 (br s, 1H), 3.85−3.58 (m, 4H),
1.95−1.75 (m, 2H), 1.63 (br s, 1H). ESI-MS m/z: 209 [M + H]+, 231
[M + Na]+.
3,4-Dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidine (16). To a
stirred solution of alcohol 15 (1.02 g, 4.90 mmol) in dry dichloro-
methane (50.0 mL) cooled to 0 °C, TEA (2.05 mL, 14.70 mmol) and
mesyl chloride (570 μL, 7.35 mmol) were added and the mixture was
stirred at 25 °C under Ar atmosphere for 1.5 h. Methanol (300 μL) was
added to quench the excess of mesyl chloride, and the reaction was
treated with a further amount of TEA (2.05 mL, 14.70 mmol) and
stirred at 50 °C for 1.5 h. Water was added, and the aqueous phase was
extracted with dichloromethane (3 × 15.0 mL). The combined organic
layers were dried over Na2SO4, filtered, and evaporated. The crude was
suspended in ethyl acetate and stirred at reflux for 15 min, then 1 h at
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25 °C, and finally cooled to 0 °C. The precipitate was filtered and
washed with cold ethyl acetate to obtain pure compound 16 (865 mg,
93% yield) as a dark solid. 1H NMR (300 MHz, CDCl3) δ 7.19 (t, J =
7.8 Hz, 2H), 6.99 (t, J = 7.6 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 3.78 (t, J =
6.0 Hz, 2H), 3.57 (t, J = 5.5 Hz, 2H), 2.10−1.97 (m, 2H). ESI-MS m/z:
191 [M + H]+, 213 [M + Na]+.
(E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)-4-methylbenzenesul-
fonamide (17). A solution of 4-toluenesulfonamide (570 mg,
3.33 mmol) and (3,4-methylendioxy)benzaldehyde (10, 500 mg,
3.33 mmol) in dry toluene (20.0 mL) was stirred at 120 °C before
adding BF3·Et2O (65 μL, 0.53 mmol). The reaction was stirred at reflux
under Ar atmosphere for 12 h. The solvent was removed under reduced
pressure, and crude imine 17 (quantitative yield) was used in the
following step without any further purification. ESI-MS m/z: 304
[M + H]+.
trans-4-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)-1-tosylaze-
tidin-2-one ((±)-18). To a stirred solution of 4-fluorophenylacetic acid
(89 mg, 0.58 mmol) in dry dichloromethane (10.0 mL) cooled to 0 °C,
tosyl chloride (165 mg, 0.87 mmol) and DIPEA (150 μL, 0.87 mmol)
were added and the reaction was stirred under Ar atmosphere for
30 min. Then, a solution of imine 17 (150 mg, 0.58 mmol) in dry
dichloromethane was added, followed by the addition of catalyst 16
(23 mg, 0.12 mmol) and DIPEA (150 μL, 0.87 mmol). The mixture was
stirred at 25 °C for 5 h before adding a 2N solution of HCl. The aqueous
phase was extracted with dichloromethane (3 × 10.0 mL), and the
combined organic layers were dried over Na2SO4, filtered, and evapo-
rated. The crude was purified by means of flash-chromatography on
silica gel (1:5 ethyl acetate/n-hexane) to afford pure compound (±)-18
(100 mg, 40% yield) as a slightly yellow oil. 1H NMR (300 MHz,
CDCl3) δ 7.73 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.09−6.93
(m, 4H), 6.79−6.73 (m, 2H), 6.67 (s, 1H), 5.97 (s, 2H), 4.83 (d, J =
3.3 Hz, 1H), 4.20 (d, J = 3.2 Hz, 1H), 2.45 (s, 3H). ESI-MS m/z: 440
[M + H]+, 462 [M + Na]+.
Enzyme Assays.MGL and FAAH activities were detected by using
different enzymatic sources. In particular, 2-AG hydrolysis was
measured by incubating the 10000g cytosolic fraction of the com-
mercially available human recombinant MGL (0.05 μg/sample; Cayman
Chemicals, Ann Arbor,MI, USA) in Tris-HCl 50mM, at pH 7.0 at 37 °C
for 20 min, with synthetic 2-arachidonoyl-[3H]-glycerol (40 Ci/mmol,
ARC St. Louis, MO, USA) properly diluted with 2-AG (Cayman
Chemicals, Ann Arbor, MI, USA). After incubation, the amount of [3H]-
glycerol produced wasmeasured by scintillation counting of the aqueous
phase after extraction of the incubation mixture with 2 volumes of
CHCl3/MeOH 1:1 (by vol.). For time-course experiments, the
effect of compounds on MGL activity was measured after 10 min of
preincubation with the enzyme followed by a 20 min of incubation with
the specific substrate. AEA hydrolysis was measured by incubating the
10000g membrane fraction of rat brain (70 μg/sample) or the
commercially available human recombinant FAAH (2 μg/sample;
Cayman Chemicals, Ann Arbor, MI, USA) in Tris−HCl 50 mM, at
pH 9.5 at 37 °C for 30 min, with synthetic N-arachidonoyl-[14C]-
ethanolamine (110 mCi/mmol, ARC St. Louis, MO, USA) properly
diluted with AEA (Tocris Bioscience, Avonmouth, Bristol, UK). After
incubation, the amount of [14C]-ethanolamine produced was measured
by scintillation counting of the aqueous phase after extraction of the
incubation mixture with 2 volumes of CHCl3/MeOH 1:1 (by vol).
Binding Assays.Membranes from HEK-293 cells stably transfected
with the human recombinant CB1 (Bmax = 2.9 pmol/mg protein) and
human recombinant CB2 (Bmax = 6.0 pmol/mg protein) were incubated
with [3H]-CP-55940 (0.4 nM/Kd = 0.11 nM and 0.53 nM/Kd =
0.19 nM, respectively, for CB1 and CB2) as the high affinity ligand and
displaced with 10 μMWIN 55212-2 as the heterologous competitor for
nonspecific binding (Ki values 8.8 and 0.9 nM, respectively, for CB1 and
CB2). All compounds were tested following the procedure described by
the manufacturer (PerkinElmer, Italia). Displacement curves were
generated by incubating drugs with [3H]-CP-55,940 for 90min at 30 °C.
Mass Studies. MGL Purification. Purified MGL protein was pre-
pared as described by King and co-workers12 with minor modification.
Briefly, rMGL cDNA was cloned in the pET15b vector containing an
N-terminal histidine tag (Novagen, La Jolla, CA), and the protein was
expressed in Rosetta 2(DE3)pLysS Escherichia coli cells (Novagen)
using 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The cells
were collected in lysis buffer (50 mM HEPES, pH 7.4, 300 mM NaCl,
10 mMMgCl2, 3 mM β-mercaptoethanol, 0.5 mM benzamidine, 10 μM
E-64, and 10 μg/mL aprotinin), homogenized, and the soluble fraction
was loaded onto a TALON column (Clontech, Mountain View, CA)
equilibrated with 50 mM HEPES (pH 7.4), 300 mM NaCl, 3 mM
β-mercaptoethanol, 0.1% Triton X-100 (buffer A). After wash, the
protein was eluted from the column by using a step gradient of imidazole
ranging from 10 to 200 mM imidazole in buffer A.
Incubation of MGL with 4a. Purified rMGLwas incubated with 4a at
a molar ratio of 1:10, for 1 h at 37 °C. The incubation buffer was the
same used for the final MGL purification (buffer A plus imidazole).
A reference incubation with DMSO was also included.
Intact MGL Analysis. After incubation, intact MGL was centrifuged
(10000g for 5 min). A small aliquot of the supernatant was diluted
10-fold in water added with 0.1% formic acid and was analyzed by
LC-MS using a Synapt G2 qTOF mass spectrometer coupled with an
Acquity UPLC system. The protein was loaded on a BEH C4 column
(1 mm × 100 mm) and eluted with a linear gradient of acetonitrile in
water (both added with 0.1% formic acid). Column and LC-MS/MS
system were purchased from Waters, Milford, USA. Mass spectra were
acquired in positive ion mode in the 500−4000 m/z range. Leucine
encephalin was infused in the ion source at 2 ng/mL as lock mass for
spectra recalibration.
Bottom-Up Analysis of MGL. After the incubation process reported
above, MGLwas digested with trypsin (proteomic grade, Sigma, Milano,
Italia) at 1:50 ratio (w/w) at 37 °C for 12 h. After digestion, the sample
was centrifuged at 10000g for 5 min. A small aliquot of the supernatant
was diluted 10-fold in water added with 0.1% formic acid and was
analyzed by LC-MS/MS using the same system described above. The
column was a BEH C18 (1 mm × 100 mm) purchased from Waters.
Peptides were eluted with a 12 min, 3−60% gradient of acetonitrile in
water. Tandem mass data were acquired in data dependent acquisition
mode, selecting multiple charged states as precursors. Collision energy
was automatically set by the acquisition software (Supporting
Information, Figure S3). We incubated the purified MGL with 4a, or
control DMSO, at a molar ratio of 1:10 for 1 h at 37 °C. Then, the
proteins were digested with trypsin at 37 °C for 12 h, and the tryptic
fragments were analyzed by LC-MS/MS as described above
(Supporting Information, Figure S4). We compared the mass spectra
of the native peptide (m/z = 1067, red) and the modified peptide from
the 4a-treated MGL (m/z = 1146, green). Compared to the fragments
from naive MGL, 4a adducts display a mass increase of 395 Da
(Supporting Information, Figure S5). The amino acid sequence shown
on the top corresponds to MGL tryptic peptide 110−160, bearing six
serine residues. MS/MS spectra of m/z 1067 (naiv̈e, bottom) and m/z
1146 (4a adduct, top) both display the y fragment ion series for a part of
the peptide, as indicated in Figure S5. From this analysis, three Ser
residues are excluded from being the binding site of compound 4a
(Supporting Information, Figure S6). Following a closer investigation of
the tandem mass spectra, two internal acylium ions were found. These
ions are unmatched between MS/MS spectra of m/z 1067 (naiv̈e) and
m/z 1146 (4a adduct). In particular, the presence of internal acylium ion
EVPVFLLGHS(+395)MGG in the 4a−adduct tandem mass spectrum
only indicates that compound 4a binds to the catalytic Ser122 as
represented in Figure 2C.
Chiral Resolution of Amine (±)-6a. Racemic mixture (±)-6a was
separated by using a cellulose-carbamate (OD) column (Daicel)
eluted with a mixture of 50% of 2-propanol in n-hexane as eluent,
flow 1 mL/min, injection volume 50 μL. This method allowed us to
efficiently split the two enantiomers that were collected and analyzed
before the calculation of the α-value. The first peak of the chromatogram
corresponds to the (+)-enantiomer ([α]20
D = +68.88), and the second
one was the (−)-enantiomer ([α]20D = −69.05) (Supporting Infor-
mation, Figure S2). Both the fractions were analyzed after collection to
check their optical purity. The analytical conditions were identical to
those above-described for the racemate separation. In Supporting
Information, Figure S2 are reported the chromatograms obtained for
respectively (+)-6a and (−)-6a.
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Stereochemical Characterization of (+)-trans-6a. Experimental
ECD and UV spectroscopic analysis was carried out at 25 °C on a Jasco
(Tokyo, Japan) J-810 spectropolarimeter equipped with a PTC-423S
Peltier-type temperature control system, using a 2 nm spectral band-
width, a 50 nm min−1 scanning speed, and a 2 s data integration time;
spectra were averaged over three accumulation cycles. Quartz cells
(Hellma, Milan, Italy) with a 1 mm path length were used to measure
spectra in the 320−200 nm spectral range. Samples for electronic ECD
and UV spectroscopic analysis on (+)-trans-6a were prepared using
HPLC-grade 2-propanol (Sigma-Aldrich, Milan, Italy) at a 135 μM
concentration.
Computational Spectroscopy.The theoretical chiroptical properties
of (3R,4S)-6a (Supporting Information, Figure S8) were determined
according to the standard protocol for stereochemical characterization
by time-dependent density functional theory (TD-DFT) calculations.33
A preliminary conformational search was performed by molecular
mechanics (MM) calculations using the MMFF94s force field34 and the
Spartan’02 software (Spartan’02 Wave function, Inc., Irvine, CA, 2002).
DFT geometry optimization and frequency calculations were carried out
on the 15 conformers, labeled (R,S)-6a1−6a15, having relative MM
energy (ΔEMM) below 3 kcal mol−1, using the Gaussian 09 software
(Gaussian09, Revision C.01; Gaussian Inc.: Wallingford CT, 2010). The
B97D functional35 the TZ2P basis set consisting in Dunning’s [5s3p/3s]
contraction of Huzinaga’s primitive [10s6p/5s] set with two sets of
polarization functions (αp = 1.5, 0.375 for H; αd = 1.5, 0.375 for C; αd =
1.6, 0.4 for N; αd = 1.7, 0.425 for O; αd = 2.0, 0.5 for F) and the IEFPCM
solvation model36 for 2-propanol were employed. Conformational
clustering was performed with a RMSD threshold value of 0.01 Å for
heavy atoms; conformer (R,S)-6a4 converged to the same geometry as
conformer (R,S)-6a1 and was consequently not considered in further
calculations. A detailed structural description of conformers (R,S)-6a1−
6a15 is given in Supporting Information, Tables S2 and S3 and Figure
S9, while thermodynamic data are reported in Supporting Information,
Table S4; the optimized structure of the lowest-energy conformer of
(3R,4S)-6a and (R,S)-6a13, is depicted in Supporting Information,
Figure S10. TD-DFT calculations were also carried out using the
Gaussian 09 software (Gaussian09, Revision C.01; Gaussian Inc.:
Wallingford CT, 2010). The PBE0 functional37,38 was used in
combination with the TZ2P basis set and the IEFPCM solvation
model for 2-propanol; calculations were performed on all optimized
conformers. Theoretical values of oscillator strength ( f j), rotational
strength in dipole velocity formalism (Rj), and excitation energies
(expressed as wavelengths, λj) were calculated for the 50 lowest-energy
electronic transitions of each optimized conformer and are reported in
Supporting Information, Tables S5 and S6. The theoretical spectra of
optimized conformers were then derived by approximation of f j and Rj
values to Gaussian bands with a Δσ value of 0.25 eV.39 The theoretical
UV and ECD spectra of (3R,4S)-6a were finally derived as the weighted
average of the contribution of all conformers, according to their
equilibrium populations at 298.15 K and 1 atm (χ) as determined by
Boltzmann statistics based on relative free energies (ΔG) and compared
to the experimental spectra (Figure 1).
Computational Studies. All calculations performed in this work
were carried out on two CoolerMaster Centurion 5 (Intel Core-i5 Quad
CPUQ6600@ 2.40 GHz) with Ubuntu 10.04 LTS (long-term support)
operating system running Maestro 9.2 (Schrödinger, LLC, New York,
NY, 2011) and GOLD 5.2 (The Cambridge Crystallographic Data
Centre, Cambridge, UK). All the pictures presented in this study were
generated by PyMOL (PyMOL v1.6-alpha; Schrödinger, LLC, New
York, 2013).
Molecules Preparation. Three-dimensional structures of both
enantiomers of compound (±)-4a were built by means of Maestro
(Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011).
Molecular energy minimizations were performed by means of
MacroModel using the Optimized Potentials for Liquid Simulations-
all atom (OPLS-AA) force field 2005.40 The solvent effects are simulated
using the analytical Generalized-Born/Surface Area (GB/SA) model,41
and no cutoff for nonbonded interactions was selected. Polak−Ribiere
conjugate gradient (PRCG) method with 1000 maximum iterations and
0.001 gradient convergence threshold was employed. Compound 4a
was treated by LigPrep application (LigPrep, version 2.5, Schrödinger,
LLC, New York, NY, 2011), implemented in Maestro suite 2011, gene-
rating the most probable ionization state of any possible enantiomers
and tautomers at cellular pH value (7 ± 0.5).
Protein Preparation. The three-dimensional structures of the hMGL
and hFAAH were taken from PDB (hMGL PDB ID, 3PE6;42 hFAAH
PDB ID, 3PPM43) and imported into Schrödinger Maestro molecular
modeling environment. The structures were submitted to Protein
Preparation Wizard implemented in Maestro suite 2011 (Protein
Preparation Wizard workflow 2011). This protocol, through a series of
computational steps, allowed us to obtain a reasonable starting structure
of the proteins for molecular docking calculations by a series of com-
putational steps. In particular, we performed three steps to (1) add
hydrogens, (2) optimize the orientation of hydroxyl groups, Asn, and
Gln, and the protonation state of His, and (3) perform a constrained
refinement with the impref utility, setting the max RMSD of 0.30. The
impref utility consists of a cycles of energy minimization based on the
impact molecular mechanics engine and on the OPLS_2005 force
field.40
Noncovalent Docking. Noncovalent docking studies were carried
out by Glide (Grid-Based Ligand Docking with Energetics) (Glide,
version 5.7, Schrödinger, LLC, New York, 2011) using the ligands and
proteins prepared as above-mentioned, applying Glide extra precision
(XP) method, as previously reported.44 Energy grids were prepared
using default value of protein atom scaling factor (1.0 Å) within a
cubic box centered on the catalytic Ser122 (for hMGL) and Ser241
(for hFAAH, Figure 5). After grid generation, the ligands were docked
into the enzymes with default parameters (no constraints were added).
The number of poses entered to postdocking minimization was set
to 50. Glide XP score was evaluated.
Covalent Docking. Concerning the covalent docking available in
GOLD 5.2 program,23 the representative poses of the most populated
cluster of docked solutions obtained by Glide for both enantiomers of
compound 4a into hMGL enzyme were redocked into binding site,
through a covalent linkage between electrophilic carbon atom close to
the triazole moiety and the hydroxyl side chain of the catalytic residue
(Ser122). In fact, both protein and ligand files were set up with the link
atom included. During docking runs, the link atom in the ligand is forced
to fit onto the link atom in the protein. To ensure that the geometry of
the bound ligand was correct, an angle-bending energy term for the link
atom was included in the calculation of the fitness score.45 Both enan-
tiomers of compound 4a was docked 50 times with early termination if
the top three poses were within 1.5 Å RMSD. The obtained hMGL-
(3R,4S)-4a and hMGL-(3S,4R)-4a tetrahedral complexes was energy
minimized using MacroModel using the Optimized Potentials for
Liquid Simulations-All Atom (OPLS-AA) force field 2005.40 The
solvent effects are simulated using the analytical Generalized-Born/
Surface Area (GB/SA) model,41 and no cutoff for nonbonded inter-
actions was selected. Polak−Ribiere conjugate gradient (PRCG) method
with 100000 maximum iterations and 0.001 gradient convergence
threshold was employed.
Free-Binding Energies Calculation. The Prime/MM-GBSA method
implemented in Prime software (Prime, version 3.0, Schrödinger, LLC,
New York, 2011) consists in computing the change between the free and
the complex state of both the ligand and the protein after energy mini-
mization. The technique was used on the docking complexes (hMGL-
(3R,4S)-4a and hMGL-(3S,4R)-4a; hFAAH-(3R,4S)-4a and hFAAH-
(3S,4R)-4a) in order to calculate the free-binding energy (ΔGbind).
Prime/MM-GBSA was used employing the calculation of ligand strain
energies and using the minimization as sampling method, defining as
flexible residues, those comprised in 10 Å from the ligand.
Selectivity in an Affinity-Based Proteomic Profiling (ABPP)
Assay. Rat brain membranes were prepared according to previously
reported methods and diluted to 1 mg/mL prior to use.46 Proteomes
(50 μL) were preincubated with either DMSO or 1−1000 nM
concentrations of inhibitor at 37 °C. After 20 min, FP-Rh (1.0 μL,
50 μM in DMSO, a kind gift of Ben Cravatt) was added and the mixture
was incubated for another 30 min at 37 °C. Reactions were quenched
with SDS loading buffer (12.5 μL, 5×) and run on SDS-PAGE (sodium
dodecyl sulfate polyacrylamide gel electrophoresis).47 Following gel
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imaging, serine hydrolase activity was determined by measuring fluo-
rescent intensity of gel bands corresponding to MAGL, ABHD6, and
FAAH using ImageJ 1.43u software.
Mutagenicity Studies and Pharmacokinetic Profiling Proce-
dures. Ames Test. Ames test was performed as previously described.48
Solubility and Chemical Stability. Standard and sample solutions are
prepared from a 10 mM DMSO stock solution using an automated
dilution procedure. For compound 4a, three solutions are prepared; one
to be used as standard and the other two as test solutions.
• Standard: 250 μM standard solution in acetonitrile/buffer, with a
final DMSO content of 2.5% (v/v).
• Test sample for pH 3.0:250 μM sample solution in acetic acid
50 mM, pH = 3, with a final DMSO content of 2.5% (v/v).
• Test sample for pH 7.4: a 250 μM sample solution in ammonium
acetate buffer 50 mM, pH = 7.4, with a final DMSO content of
2.5% (v/v).
The 250 μM product suspensions/solutions in the aqueous buffers
are prepared directly in Millipore MultiScreen-96 filter plates (0.4 μm
PTCE membrane) and sealed. Plates are left for 24 h at rt under
orbital shaking to achieve “pseudo-thermodynamic equilibrium” and to
presaturate themembrane filter. Product suspensions/solutions are then
filtered using centrifugation, diluted 1:2 with the same buffer solution,
and analyzed by UPLC/UV/TOF-MS, using UV-detection at 254 nm
for quantitation. An aliquot of the pH 7.4 solution is transferred in a
microplate, left for 24 h at rt, and analyzed by UPLC/UV/TOF-MS for
the chemical stability assay.
Metabolic Stability on Human CYP3A4. Compound 4a in 10 mM
DMSO solution was added to an incubation mixture in a 96-well
microplate containing 20 pmol/mL of hCYP3A4 (0.1−0.2 mg/mL
protein). The mixture is split in two aliquots: one receiving a NADPH
regenerating system, the other an equal amount of phosphate buffer.
The final substrate concentration is 1 μM along with 0.25% of organic
solvent. Incubation proceeds for 1 h at 37 °C and is then stopped by
addition of MeCN to precipitate proteins.
Permeability Assay (PAMPA). Compound 4a (10 μM in HBSS +
Hepes buffer) are added to the donor chamber and incubated (together
with a reference compound, warfarin, to verify membrane integrity) for
4 h at 37 °C and 80% humidity. Concentrations of reference, donor, and
acceptor solutions are measured by UPLC-MS-TOF (references, donor,
and acceptor are injected in UPLC-MS in this order for compare the MS
quantitative signal).
Brain Penetration. Transport across the blood−brain barrier was
tested using a human in vitro blood−brain barrier model consisting of a
coculture of endothelial cells derived from hematopoietic stem cells and
pericytes.49 After 6 days of coculture, compound 4a (100 μM in Ringer
solution + Hepes) was added to the luminal side of endothelial cells
(together with a nonpermeant compound, Lucifer yellow, to verify
endothelium integrity) and incubated for 20, 40, and 60 min at 37 °C
and 80% humidity. Concentrations were measured at luminal and
abluminal sides using fluorescence detection (synergy H1 multiplates
reader; BioTek) for Lucifer yellow and LC-UV analysis for 4a. Papp was
determined according the equation Papp = J/ACo, where J is the rate of
appearance of the drug at the abluminal side, Co is the initial concen-
tration at the luminal side, and A is the surface area of the filter.50
Isolated Rat Heart Preparation and Perfusion. All animal care
and experimental protocols conformed to the European Union
Guidelines for the Care and the Use of Laboratory Animals (European
Union Directive 2010/63/EU) and were approved by the Italian
Department of Health (666/2015-PR). Male Sprague−Dawley rats
(300 g; Charles River Italia, Calco, Italy) were anaesthetized (ip) with a
mixture of Zoletil 100 (7.5 mg kg−1 tiletamine and 7.5 mg kg−1
zolazepam; Virbac Srl, Milano, Italy) and Xilor (4 mg/kg xylazine; Bio
98, San Lazzaro, Italy) containing heparin (5000 U/kg), decapitated,
and bled. The hearts, spontaneously beating, were rapidly explanted and
mounted on a Langendorff apparatus for retrograde perfusion via the
aorta at a constant flow rate of 10 mL/min with a Krebs−Henseleit
solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2
2.5, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, glucose 11.5, Na pyruvate 2,
and EDTA 0.5, bubbled with a 95% O2−5% CO2 gas mixture (pH 7.4),
and kept at 37 °C, as described elsewhere.51
The hearts were allowed to equilibrate for at least 20 min before drug
exposure.
Heart contractility was measured as left ventricle pressure (LVP) by
means of latex balloon, inserted into the left ventricle via the mitral valve
and connected to a pressure transducer (BLPR, WPI, Berlin, Germany).
The balloon was inflated with deionized water from a microsyringe until
a left ventricular end diastolic pressure of 10 mmHg was obtained.
Alteration in coronary perfusion pressure (CPP), arising from
changes in coronary vascular resistance, were recorded by pressure
transducer (BLPR, WPI, Berlin, Germany) placed in the inflow line.
A surface electrocardiogram (ECG) was recorded at a sampling rate
of 1 kHz by means of two steel electrodes, one placed on the apex and
the other on the left atrium of the heart. The ECG analysis included
the following measurements: RR (cycle length), HR (frequency), PQ
(atrioventricular conduction time), QRS (intraventricular conduction
time), and QT (overall action potential duration).52
LVP, CPP, and ECG were recorded with a digital PowerLab data
acquisition system (PowerLab 8/30; ADInstruments, Castle Hill,
Australia) and analyzed by using Chart Pro for Windows software
(PowerLab; ADInstruments, Castle Hill, Australia).
LVP was calculated by subtracting the left ventricular diastolic
pressure from the left ventricular systolic pressure. As the QT interval is
affected by heart rate changes (e.g., it shortens with rapid heart rate),
Bazett’s formula (QTc = QT/(RR)1/2) was routinely used to avoid
confounding effects.
Compound 4a was dissolved in DMSO. Solvents failed to alter the
response of the preparations (data not shown).
Statistical Analysis. Data are reported as mean ± SEM; n (indicated
in parentheses) represents the number of rat hearts. Analysis of data was
accomplished using GraphPad Prism version 5.04 (GraphPad Software,
U.S.A.). Statistical analyses and significance as measured by repeated
measures ANOVA (followed by Dunnett’s post test) were obtained
using GraphPad InStat version 3.06 (GraphPad Software, U.S.A.). In all
comparisons, P < 0.05 was considered significant.
Pharmacological in Vivo Studies. Animal handling was carried
out according to the European Community guidelines for animal care
(DL 116/92, application of the European Communities Council
Directive 86/609/EEC). The ethical policy of the University of Florence
and the Second University of Naples conforms with the Guide for the
Care and Use of Laboratory Animals of the U.S. National Institutes of
Health (NIH Publication no. 85-23, revised 1996; University of
Florence assurance number A5278-01). Formal approval to conduct the
experiments described herein was obtained from the animal subjects
review board of the University of Florence and Second University of
Naples.
Formalin Experiments. For the formalin experiments, male CD-1
mice received formalin (1.25% in saline, 30 μL) in the dorsal surface of
one side of the hind paw. Each mouse was randomly assigned to one of
the experimental groups (n = 6) and placed in a plexiglass cage and
allowed to move freely for 15−20 min. A mirror was placed at a 45°
angle under the cage to allow full view of the hind paws. Lifting, favoring,
licking, shaking, and flinching of the injected paw were recorded as
nociceptive responses.53 The total time of the nociceptive response was
measured every 5 min and expressed in min (mean ± SEM). Recording
of nociceptive behavior commenced immediately after formalin
injection and was continued for 60 min. Mice received vehicle (0.5%
DMSO in saline) or different doses of 4a (0.1 or 0.3 mg/kg, ip) 10 min
before formalin injection. For the combination experiments, 20 or 21
(1 mg/kg, ip) were injected before 4a. For the oxyplatin experiment,
male Swiss albino mice (23−25 g) were used. The animals were fed with
a standard laboratory diet and tap water ad libitum and kept at 23± 1 °C
with a 12 h light/dark cycle, light on at 7 a.m.
Extraction, Purification, and Analysis of 2-AG Tissue Levels.
Methods. Tissues (paw skin or spinal cords) from vehicle/saline,
vehicle/formalin, compound 1a/saline, and compound 4a/formalin-
treated mice were homogenized in 5 volumes of chloroform/methanol/
Tris HCl 50 mM (2:1:1) containing 20 pmol each of d5−2-AG.
Homogenates were centrifuged at 13000g for 16 min (4 °C), and the
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aqueous phase plus debris was collected and extracted again twice with
1 volume of chloroform. The organic phases from the three extractions
were pooled and the organic solvents evaporated in a rotating
evaporator. Lyophilized samples were then stored frozen at −80 °C
under nitrogen atmosphere to be analyzed later. Lyophilized extracts
were resuspended in chloroform/methanol 99:1 by volumes. The
solutions were then purified by open bed chromatography on silica as
described.54 Fractions eluted with chloroform/methanol 9:1 by volume
(containing 2-AG) were collected, the excess solvent evaporated with a
rotating evaporator, and aliquots analyzed by isotope dilution liquid
chromatography/atmospheric pressure chemical ionization/mass spec-
trometry (LC-MS) carried out under conditions described previously
and allowing the gross purification of 2-AG. Mass spectrometric
detection was carried out in the selected ion monitoring mode using
m/z values of 384 and 379 (molecular ions +1 for deuterated and
undeuterated 2-AG). The areas of the peaks corresponding to the
1(3)-and 2-isomers of 2-AG were added together. The amounts of the
compounds were expressed as picomol/milligram of tissue.
Oxaliplatin Experiments. Oxaliplatin, a third-generation platinum
analogue, has become a first-line chemotherapy in metastatic colorectal
cancer and a valid option as adjuvant therapy in several types of cancer.55
The major dose-limiting side effect is a painful neuropathy that persists
between cycles56 and correlated with characteristic alterations of the
nervous system. Oxaliplatin neuropathy was induced in mice admin-
istering 2.4 mg/kg oxaliplatin intraperitoneally (ip) for 5 consecutive
days every week for 2 weeks (we followed Cavaletti protocol57 adapted
to mice). Oxaliplatin was dissolved in 5% glucose solution. Control
animals received an equivalent volume of 5% glucose ip (vehicle).
Behavioral tests were performed on day 14. 4a (1−30 mg/kg) was
suspended in the vehicle (1% carboxymethylcellulose) and per os (po)
acutely administered on day 14. Alternatively, 4a (10 mg/kg) was daily
administered starting from the first day of oxaliplatin treatment to
day 13; behavioral measurements were performed 24 h after the last
administration. For analgesia measurements performed by Hot plate
test, animals were acutely po treated (4a, 3 and 10 mg/kg).
Cold and Hot Plate Tests. The cold plate test was performed
placing animals in a stainless box (12 cm × 20 cm × 10 cm) with a cold
plate as floor. The temperature of the cold plate was kept constant at
4 °C ± 1 °C. Pain-related behaviors (i.e., lifting and licking of the hind
paw) were observed, and the time (s) of the first sign was recorded. The
cutoff time of the latency of paw lifting or licking was set at 60 s.
Hot-plate test (Supporting Information, Table S1) was carried out
accordingly withO’Callaghan andHolzman.58Mice were placed inside a
stainless steel container, thermostatically set at 52.5 ± 0.1 °C in a
precision water-bath from KW Mechanical Workshop, Siena, Italy.
Reaction times (s) were measured with a stop-watch before and at
regular intervals up to a maximum of 60 min after treatment. The end
point used was the licking of the fore or hind paws. Before treating
animals with 4a, a pretest was performed: those mice scoring below 12
and over 18 s were rejected. An arbitrary cutoff time of 45 s was adopted.
Animals and EAE Induction. Female mice (C57BL/6J; 18−20 g,
6−8 weeks) were obtained from Charles River (Calco, Italy) and were
housed in the animal facility of DIFAR, Section of Pharmacology and
Toxicology (authorization no. 484 of June 8, 2004). Female mice were
immunized according to a standard protocol previously described,59
with minor modifications. Briefly, animals were subcutaneously injected
with incomplete Freund’s adjuvant containing 4 mg/mLMycobacterium
tuberculosis (strain H37Ra) and 200 μg of the MOG35-55 peptide.
Immunization with MOG35-55 was followed by ip administration of 250
ng of pertussis toxin on day 0 and after 48 h. Clinical scores (0 = healthy,
1 = limp tail, 2 = ataxia and/or paresis of hindlimbs, 3 = paralysis of
hindlimbs and/or paresis of forelimbs, 4 = tetraparalysis, 5 = moribund
or death) were recorded daily. All efforts were made to minimize animal
suffering and to use the minimal number of animals necessary to
produce reliable results.
All the experimental procedures described here were in accordance
with the Italian legislation (no. 26, March 4, 2014) and the European
legislation (2010/63/UE, September 22, 2010) and the ARRIVE
guidelines, and they were approved by the Italian Ministry of Health
(protocol number no. 50/2011-B). Experiments were performed
following the Guidelines for Animal Care and Use of the National
Institutes of Health.
Histological Analysis. Luxol Fast Blue (LFB). Luxol Fast Blue is an
histological staining for myelin.
Spinal cord were formalin-fixed and cryoprotected in a 20 and 30%
sucrose solution. Spinal cords were cut with a cryostat, and 10 μm thick
coronal sections were collected. Tissue sections were immersed
overnight in 0.1% Luxol Fast Blue solution (Solvent Blue 38, Sigma-
Aldrich, St. Louis, MO, USA) at 56−60 °C. Sections were rinsed in
deionized water. Differentiation was initiated with immersion in 0.05%
aqueous lithium carbonate for 15−17 s, followed by differentiation in
multiple immersions in fresh 70% ethanol until gray, and white matter
could be distinguished and nuclei decolourized. After washing in
deionized water, sections were immersed in 0.8% periodic acid (Sigma−
Aldrich, St Louis, MO, USA) for 10 min and then rinsed in distillated
water. Sections were incubated with Schiff’s Reagent (Bio Optica,
Milan, Italy) for 20 min, dehydrated in 50 and 100% ethanol and xylene
(3× 1min each), and finally coverslipped. Sections were examined using
an Olympus BX40 microscope and photographed using a digital camera
Olympus DP50 (Olympus, Milan, Italy).
Immunofluorescence Staining. IBA1. Formalin-fixed cryostat
sections (10 μm) were washed 3× phosphate-buffered saline (PBS) and
0.3% Triton X-100 for 5 min and then were incubated, at room
temperature, for 1 h in blocking solution (PBS, 0.3% Triton X-100, 5%
albumin bovine serum; PBST). Slices were incubated overnight at 4 °C
in PBST containing rabbit primary antibody directed against ionized
calcium binding adapter molecule 1 (Iba1; rabbit, 1:1000; Wako,
Richmond, VA, USA) for microglial staining. The following day, slides
were washed 3× PBS, 0.3% Triton X-100 for 5 min and then sections
were incubated in goat antirabbit IgG secondary antibody labeled
with Alexa Fluor 568 (1:500; Invitrogen, Carlsbad, USA) and DAPI
(4′,6-diamidin-2-fenilindolo; 1:2000; Life Technologies-Thermo scien-
tific, Rockford, IL, USA), a nuclei marker, in PBST at room temperature
for 2 h, in the dark. After 3× PBS 0.3% Triton X-100 wash for 10 min,
slices were mounted using ProLong Gold (Life Technologies-Thermo
scientific, Rockford, IL, USA) as a mounting medium.
Negative control sections (no exposure to the primary antisera) were
processed concurrently with the other sections for immunohistochem-
ical studies in order to exclude the presence of nonspecific immuno-
fluorescent staining or cross-immunostaining.
Images were acquired by using an Olympus BX63 microscope
equipped with an Olympus XM10 camera and coupled to CellSense
Dimension Software (Olympus, Milan, Italy).
Quantitative analysis of Iba1-positive cells was performed by
collecting a field through a 10× 0.25NA objective in the white matter
anterior fasciculus of three mice spinal cord for group. Iba1-positive cells
were counted in the anterior fasciculus using the “cell counter” plugin of
ImageJ (NIH, Bethesda, Maryland, USA).
Statistical Analysis for Histological Measurements.Number of
Iba1 positive cells/optic field are performed on three rats per group,
evaluating section of anterior fasciculus in the white matter spinal cord
for each animal. Data are expressed as mean ± SEM and One-Way
ANOVA followed by Bonferroni’s post hoc comparison test was per-
formed. Data were analyzed using the Origin 8.1 software (OriginLab,
Northampton, USA). Differences were considered significant at a P < 0.05.
Drug Treatments. Starting at 6 days post immunization (dpi), mice
were randomly assigned to the following groups: untreated EAE mice,
4a (3 mg/kg ip)-treated EAE mice; 4a (3 mg/kg ip)/20 (1 mg/kg)-
treated EAE mice; 4a (3 mg/kg ip)/21 (1 mg/kg)-treated EAE mice.
20 and 21 were administered 10 min before 4a.
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